UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2021~~2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 000-55413

Cell Source, Inc.

(Exact name of registrant as specified in its charter)

Nevada

32-0379665

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

57 West ~~57th~~57^th Street, Suite 400

New York, NY 10019

(Address of principal executive offices)

(646) 416-7896

(Issuer’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any news or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November ~~10, 2021,~~30, 2022, the registrant had ~~33,723,554~~35,252,389 shares of $0.001 par value common stock outstanding.

CELL SOURCE, INC. AND SUBSIDIARY

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER~~JUNE 30, ~~2021~~2022

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.		3

Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2021~~2022 (Unaudited) and December 31, ~~2020~~2021		3

Unaudited Condensed Consolidated Statements of Operations for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021		4

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficiency for the ~~Nine~~Three and Six Months Ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021		5

Unaudited Condensed Consolidated Statements of Cash Flows for the ~~Nine~~Six Months Ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021		7

Notes to Unaudited Condensed Consolidated Financial Statements		8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.		1615

Item 3. Quantitative and Qualitative Disclosures About Market Risk.		2220

Item 4. Controls and Procedures.		2220

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.		2321

Item 1A. Risk Factors.		2321

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.		2321

Item 3. Defaults Upon Senior Securities.		2422

Item 4. Mine Safety Disclosures.		2422

Item 5. Other Information.		2422

Item 6. Exhibits.		2422

SIGNATURES		2523

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

CELL SOURCE, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,			June 30,			December 31,
	2021			2020			2022			2021
	(Unaudited)						(Unaudited)
Assets
Current Assets:
Cash	$	599,454		$	241,619		$	2,597		$	93,095
Prepaid expenses		243,876			177,569			25,911			203,750
Other current assets		17,344			29,651			16,132			16,922
Total Current Assets		860,674			448,839
Restricted cash		-			3,500
Total Assets	$	860,674		$	452,339		$	44,640		$	313,767

Liabilities and Stockholders’ Deficiency

Current Liabilities:
Accounts payable	$	285,162		$	193,095		$	382,009		$	223,041
Accrued expenses		949,933			1,159,950			1,500,937			1,097,021
Accrued expenses - related parties		101,201			198,701
Accrued expenses - related party								72,000			72,000
Accrued interest		863,296			671,968			759,829			725,308
Accrued interest - related parties		395,125			325,276			814,192			456,917
Accrued compensation		760,941			724,185			798,240			766,102
Notes payable, net of debt discount of $30,595 and $0 as of June 30, 2022 and December 31, 2021, respectively								750,499			759,912
Notes payable - related parties								150,000			150,000
Convertible notes payable, net of debt discount of $8,233 and $71,124 as of June 30, 2022 and December 31, 2021, respectively								656,729			1,834,446
Convertible notes payable - related parties, net of debt discount of $72,922 and $0 as of June 30, 2022 and December 31, 2021, respectively								4,652,078			3,725,000
Advances payable		195,500			195,500			135,000			135,000
Advances payable - related party		100,000			100,000			100,000			100,000
Notes payable		809,912			1,013,000
Notes payable - related parties		150,000			150,000
Convertible notes payable, net of debt discount of $236,091 and $157,720 as of September 30, 2021 and December 31, 2020, respectively		5,841,730			3,417,836
Convertible notes payable - related parties		225,000			225,000
Financing liability for directors and officers insurance		124,581			-
Financing liability								-			27,926
Accrued dividend payable		246,192			25,210			39,686			67,229
Total Current Liabilities		11,048,573			8,399,721
Total Liabilities								10,811,199			10,139,902

Commitments and contingencies (Note 8)		-						-			-

Stockholders’ Deficiency:
Convertible Preferred Stock, $0.001 par value, 10,000,000 shares authorized;
Series A Convertible Preferred Stock, 1,335,000 shares designated, 1,342,195 shares issued and outstanding as of September 30, 2021 and December 31, 2020; liquidation preference of $10,294,818 and $10,091,672 as of September 30, 2021 and December 31, 2020, respectively		1,342			1,342
Series C Convertible Preferred Stock, 500,000 shares designated, 163,296 and 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively; liquidation preference of $1,242,550 and $0 as of September 30, 2021 and December 31, 2020, respectively		163			-
Convertible preferred stock, value
Common Stock, $0.001 par value, 200,000,000 shares authorized; 33,588,578 and 32,538,411 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively		33,589			32,538
Convertible Preferred Stock, $0.001 par value, 10,000,000 shares authorized; Series A Convertible Preferred Stock, 1,335,000 shares designated, 1,342,195 shares issued and outstanding as of June 30, 2022 and December 31, 2021; liquidation preference of $10,066,463 as of June 30, 2022 and December 31, 2021								1,342			1,342
Series C Convertible Preferred Stock, 500,000 shares designated, 470,109 and 272,021 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively; liquidation preference of $3,565,506 and $2,107,388 as of June 30, 2022 and December 31, 2021, respectively								470			272
Preferred stock, value
Common Stock, $0.001 par value, 200,000,000 shares authorized; 35,239,669 and 34,360,546 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively								35,240			34,361
Additional paid-in capital		20,120,422			17,724,731			22,952,986			21,316,318
Accumulated deficit		(30,343,415	)		(25,705,993	)		(33,756,597	)		(31,178,428	)
Total Stockholders’ Deficiency		(10,187,899	)		(7,947,382	)		(10,766,559	)		(9,826,135	)
Total Liabilities and Stockholders’ Deficiency	$	860,674		$	452,339		$	44,640		$	313,767

The accompanying notes are an integral part of these condensed consolidated financial statements.

CELL SOURCE, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended For the Nine Months Ended
September 30, September 30,
2021 2020 2021 2020

Operating Expenses:
Research and development $ 446,773 $ 257,546 $ 1,037,588 $ 675,017
Research and development - related party 12,500 - 60,475 111,667
General and administrative 856,059 908,099 2,333,724 2,015,624
Total Operating Expenses 1,315,332 1,165,645 3,431,787 2,802,308
Loss From Operations (1,315,332 ) (1,165,645 ) (3,431,787 ) (2,802,308 )

Other (Expense) Income:
Interest expense (191,626 ) (114,040 ) (588,314 ) (271,687 )
Interest expense - related parties (22,805 ) (12,827 ) (69,849 ) (36,708 )
Amortization of debt discount (269,805 ) (146,109 ) (547,737 ) (190,639 )
Change in fair value of derivative liabilities - - - 16,977
Gain on forgiveness of accrued interest - - 49,983 -
Gain on exchange of accrued interest for common stock - 132,502 - 132,502
Loss on extinguishment of notes payable - (1,511 ) (49,718 ) (134,202 )
Total Other Expense (484,236 ) (141,985 ) (1,205,635 ) (483,757 )
Net Loss (1,799,568 ) (1,307,630 ) (4,637,422 ) (3,286,065 )
Dividend attributable to Series A and Series C preferred stockholders (246,192 ) (226,191 ) (695,456 ) (649,381 )
Net Loss Applicable to Common Stockholders $ (2,045,760 ) $ (1,533,821 ) $ (5,332,878 ) $ (3,935,446 )

Net Loss Per Common Share - Basic and Diluted $ (0.06 ) $ (0.05 ) $ (0.16 ) $ (0.13 )

Weighted Average Common Shares Outstanding -
Basic and Diluted 33,461,141 31,846,661 32,897,010 30,334,852
(Unaudited)

2022 2021 2022 2021
For the Three Months Ended
June 30, For the Six Months Ended
June 30,
2022 2021 2022 2021

Operating Expenses:
Research and development $ 555,010 $ 355,051 $ 1,019,515 $ 590,815
Research and development - related party 14,500 12,500 29,000 47,975
General and administrative 464,367 627,548 1,038,034 1,477,665
Total Operating Expenses 1,033,877 995,099 2,086,549 2,116,455
Loss From Operations (1,033,877 ) (995,099 ) (2,086,549 ) (2,116,455 )

Other (Expense) Income:
Interest expense (63,313 ) (140,305 ) (111,725 ) (396,688 )
Interest expense - related parties (130,049 ) (22,540 ) (248,402 ) (47,044 )
Amortization of debt discount (23,151 ) (155,169 ) (89,688 ) (277,932 )
Amortization of debt discount - related party (35,204 ) - (41,805 ) -
Gain on forgiveness of accrued interest - - - 49,983
Loss on extinguishment of notes payable - - - (49,718 )
Total Other Expense (251,717 ) (318,014 ) (491,620 ) (721,399 )
Net Loss (1,285,594 ) (1,313,113 ) (2,578,169 ) (2,837,854 )
Dividend attributable to Series A and Series C preferred stockholders (244,971 ) (225,873 ) (569,888 ) (449,264 )
Net Loss Applicable to Common Stockholders $ (1,530,565 ) $ (1,538,986 ) $ (3,148,057 ) $ (3,287,118 )

Net Loss Per Common Share - Basic and Diluted $ (0.04 ) $ (0.05 ) $ (0.09 ) $ (0.10 )

Weighted Average Common Shares Outstanding - Basic and Diluted 34,438,057 32,663,482 34,419,213 32,610,275
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
CELL SOURCE, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIENCY
(Unaudited)

~~(Unaudited)~~

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021
Convertible Preferred Convertible Preferred Additional Total
Stock - Series A Stock - Series C Common Stock
Paid- In
Accumulated Stockholders’
Shares Amount Shares Amount Shares Amount Capital Deficit Deficiency

Balance, January 1, 2021 1,342,195 $ 1,342 - $ - 32,538,411 $ 32,538 $ 17,724,731 $ (25,705,993 ) $ (7,947,382 )
Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (223,391 ) - (223,391 )
Payment of dividends in kind
Payment of dividends in kind, shares

Issuance of common stock pursuant to cashless warrant exercise - - - - 125,071 125 (125 ) - -

Issuance of warrants in connection with issuance of convertible notes payable - - - - - - 196,966 - 196,966

Issuance of warrants in connection with exchange of convertible notes payable - - - - - - 139,728 - 139,728

Warrants issued in satisfaction of accrued interest - - - - - - 82,350 - 82,350

Stock-based compensation:
Common stock
Common stock, shares
Options - - - - - - 206,400 - 206,400
Warrants - - - - - - 31,276 - 31,276
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock, shares
Conversion of Series C Convertible Preferred Stock into common stock
Conversion of Series C Convertible Preferred Stock into common stock, shares
Warrants modification expense
Common stock issued in satisfaction of accrued compensation
Common stock issued in satisfaction of accrued compensation , shares
Issuance of common stock in connection with extension of notes payable
Issuance of common stock in connection with extension of notes payable, shares
Reclassification of derivative liabilities to equity
Issuance of warrants in connection with issuance of notes payable
Issuance of common stock in exchange of accrued interest
Issuance of common stock in exchange of accrued interest
Issuance of Series A Convertible Preferred Stock for cash
Issuance of Series A Convertible Preferred Stock for cash, shares
Issuance of warrants in connection with issuance of advance payable

Net loss - - - - - - - (1,524,741 ) (1,524,741 )

Balance, March 31, 2021 1,342,195 1,342 - - 32,663,482 32,663 18,157,935 (27,230,734 ) (9,038,794 )

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (225,873 ) - (225,873 )
Payment of dividends in kind - - - - 632,677 633 473,842 - 474,475

Issuance of warrants in connection with issuance of convertible notes payable - - - - - - 37,512 - 37,512

Stock-based compensation:
Common stock - - - - 5,405 5 2,535 - 2,540
Warrants - - - - - - 36,343 - 36,343

Net loss - - - - - - - (1,313,113 ) (1,313,113 )

Balance, June 30, 2021 1,342,195 1,342 - - 33,301,564 33,301 18,482,294 (28,543,847 ) (10,026,910 )

Series A and C Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (246,192 ) - (246,192 )

Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock - - 168,296 168 71,915 72 1,315,918 - 1,316,158

Conversion of Series C Convertible Preferred Stock into common stock - - (5,000 ) (5 ) 50,000 50 (45 ) - -

Warrants issued in satisfaction of accrued interest - - - - - - 165,216 - 165,216

Warrants modification expense - - - - - - 29,000 - 29,000

Common stock issued in satisfaction of accrued compensation - - - - 15,099 16 7,081 - 7,097

Issuance of warrants in connection with issuance of convertible notes payable - - - - - - 226,791 - 226,791

Stock-based compensation:
Common stock - - - - 150,000 150 70,350 - 70,500
Warrants - - - - - - 70,009 - 70,009

Net loss - - - - - - - (1,799,568 ) (1,799,568 )

Balance, September 30, 2021 1,342,195 $ 1,342 163,296 $ 163 33,588,578 $ 33,589 $ 20,120,422 $ (30,343,415 ) $ (10,187,899 )
Shares Amount Shares Amount Shares Amount Capital Deficit Deficiency
Convertible Preferred Convertible Preferred Additional Total
Stock - Series A Stock - Series C Common Stock Paid-In Accumulated Stockholders’
Shares Amount Shares Amount Shares Amount Capital Deficit Deficiency

Balance, January 1, 2022 1,342,195 $ 1,342 272,021 $ 272 34,360,546 $ 34,361 $ 21,316,318 $ (31,178,428 ) $ (9,826,135 )

Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock - - 183,422 183 76,530 76 1,432,836 - 1,433,095

Series A and C Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (324,917 ) - (324,917 )

Issuance of warrants in connection with issuance of convertible notes payable - - - - - - 8,043 - 8,043

Stock-based compensation:
Warrants - - - - - - 5,372 - 5,372
Options
Common stock
Common stock, shares
Issuance of common stock pursuant to cashless warrant exercise
Issuance of common stock pursuant to cashless warrant exercise, shares
Issuance of warrants in connection with exchange of convertible notes payable
Warrants issued in satisfaction of accrued interest

Net loss - - - - - - - (1,292,575 ) (1,292,575 )

Balance, March 31, 2022 1,342,195 1,342 455,443 455 34,437,076 34,437 22,437,652 (32,471,003 ) (9,997,117 )

Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock - - 14,666 15 5,964 6 114,452 - 114,473

Series A and C Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (244,971 ) - (244,971 )
Payment of dividends in kind - - - - 796,629 797 596,634 - 597,431

Issuance of warrants in connection with issuance of convertible notes payable and notes payable - - - - - - 49,219 - 49,219

Net loss - - - - - - - (1,285,594 ) (1,285,594 )

Balance, June 30, 2022 1,342,195 $ 1,342 470,109 $ 470 35,239,669 $ 35,240 $ 22,952,986 $ (33,756,597 ) $ (10,766,559 )

The accompanying notes are an integral part of these condensed consolidated financial statements.

5
CELL SOURCE, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIENCY – CONTINUED
(Unaudited)
Convertible Preferred Convertible Preferred Additional Total
Stock - Series A Stock - Series C Common Stock Paid-In Accumulated Stockholders’
Shares Amount Shares Amount Shares Amount Capital Deficit Deficiency

Balance, January 1, 2021 1,342,195 $ 1,342 - - 32,538,411 $ 32,538 $ 17,724,731 $ (25,705,993 ) $ (7,947,382 )

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (223,391 ) - (223,391 )

Issuance of common stock pursuant to cashless warrant exercise - - - - 125,071 125 (125 ) - -

Issuance of warrants in connection with issuance of convertible notes payable - - - - - - 196,966 - 196,966

Issuance of warrants in connection with exchange of convertible notes payable - - - - - - 139,728 - 139,728

Warrants issued in satisfaction of accrued interest - - - - - - 82,350 - 82,350

Stock-based compensation:
Options - - - - - - 206,400 - 206,400
Warrants - - - - - - 31,276 - 31,276

Net loss - - - - - - - (1,524,741 ) (1,524,741 )

Balance, March 31, 2021 1,342,195 1,342 - - 32,663,482 32,663 18,157,935 (27,230,734 ) (9,038,794 )
Balance 1,342,195 1,342 - - 32,663,482 32,663 18,157,935 (27,230,734 ) (9,038,794 )

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (225,873 ) - (225,873 )
Payment of dividends in kind - - - - 632,677 633 473,842 - 474,475

Issuance of warrants in connection with issuance of convertible notes payable - - - - - - 37,512 - 37,512

Stock-based compensation:
Common stock - - - - 5,405 5 2,535 - 2,540
Warrants - - - - - - 36,343 - 36,343

Net loss - - - - - - - (1,313,113 ) (1,313,113 )

Balance, June 30, 2021 1,342,195 $ 1,342 - $ - 33,301,564 $ 33,301 $ 18,482,294 $ (28,543,847 ) $ (10,026,910 )
Balance 1,342,195 $ 1,342 - $ - 33,301,564 $ 33,301 $ 18,482,294 $ (28,543,847 ) $ (10,026,910 )

~~(Unaudited)~~
1
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020
Convertible Preferred Convertible Preferred Additional Total
Stock - Series A Stock - Series C Common Stock Paid- In Accumulated Stockholders’
Shares Amount Shares Amount Shares Amount Capital Deficit Deficiency

Balance, January 1, 2020 1,245,083 $ 1,245 - - 27,076,762 $ 27,077 $ 15,375,565 $ (21,145,828 ) $ (5,741,941 )

Issuance of Series A Convertible Preferred Stock for cash 13,333 13 - - 99,987 - 100,000

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - - - (211,305 ) - (211,305 )

Issuance of common stock in connection with extension of notes payable - - 227,500 227 56,648 - 56,875

Reclassification of derivative liabilities to equity - - - - 345,830 - 345,830

Stock-based compensation:
Common stock - - - - 25,671 26 6,392 - 6,418

Net loss - - - - - - - (813,747 ) (813,747 )

Balance, March 31, 2020 1,258,416 1,258 - - 27,329,933 27,330 15,673,117 (21,959,575 ) (6,257,870 )

Issuance of Series A Convertible Preferred Stock for cash 3,333 3 - - 24,997 - 25,000

Issuance of common stock in connection with extension of notes payable - - 525,000 525 130,725 - 131,250

Issuance of warrants in connection with issuance of notes payable - - - - - - 161,256 - 161,256

Issuance of warrants in connection with issuance of advance payable - - - - 24,386 - 24,386

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - (211,885 ) - (211,885 )
Payment of dividends in kind - - 574,576 574 430,331 - 430,905

Stock-based compensation:
Common stock - - 1,270,000 1,270 316,230 - 317,500
Warrants - - - - 16,129 - 16,129

Net loss - - - - - - - (1,164,688 ) (1,164,688 )

Balance, June 30, 2020 1,261,749 1,261 - - 29,699,509 29,699 16,565,286 (23,124,263 ) (6,528,017 )

Balance 1,261,749 1,261 - - 29,699,509 29,699 16,565,286 (23,124,263 ) (6,528,017 )
Issuance of Series A Convertible Preferred Stock for cash 80,446 81 - - 603,266 - 603,347

Issuance of common stock in exchange of accrued interest - - 265,534 266 66,383 - 66,649

Issuance of warrants in connection with issuance of notes payable - - - - 20,098 - 20,098

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends - - - - (226,191 ) - (226,191 )

Stock-based compensation:
Options - - - - 103,600 - 103,600
Warrants - - - - 249,713 - 249,713

Net loss - - - - - - - (1,307,630 ) (1,307,630 )

Balance, September 30, 2020 1,342,195 $ 1,342 - - 29,965,043 $ 29,965 $ 17,382,155 $ (24,431,893 ) $ (7,018,431 )
Balance 1,342,195 $ 1,342 - - 29,965,043 $ 29,965 $ 17,382,155 $ (24,431,893 ) $ (7,018,431 )
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

CELL SOURCE, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

~~(Unaudited)~~
2022 2021
For The Nine Months Ended For Six Months Ended
September 30, June 30,
2021 2020 2022 2021

Cash Flows From Operating Activities:
Net loss $ (4,637,422 ) $ (3,286,065 ) $ (2,578,169 ) $ (2,837,854 )

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities - (16,977 )
Amortization of debt discount 547,737 190,639 131,493 277,932
Gain on forgiveness of accrued interest (49,983 ) - - (49,983 )
Loss on extinguishment of notes payable 49,718 134,202 - 49,718
Gain on exchange of accrued interest for common stock - (132,502 )
Non-cash interest expense - warrants 286,639 60,769 63,267 218,985
Stock-based compensation:
Options 206,400 103,600 - 206,400
Warrants 137,735 263,476 5,034 67,707
Common stock 80,137 319,396
Common Stock - 9,637
Changes in operating assets and liabilities:
Prepaid expenses 254,193 (72,687 ) 177,839 (37,695 )
Other current assets 12,307 9,355 790 21,584
Accounts payable 92,067 240,931 158,968 146,895
Accrued expenses (210,019 ) (46,990 ) 403,916 (463,996 )
Accrued expenses - related parties (97,500 ) (46,597 ) - (110,000 )
Accrued interest 369,619 207,889 (44,729 ) 223,638
Accrued interest - related parties 2,244 2,252 320,361 1,488
Accrued compensation 36,650 51,290 32,476 17,968
Net Cash Used In Operating Activities (2,919,478 ) (2,018,019 ) (1,328,754 ) (2,257,576 )

Cash Flows From Financing Activities:
Proceeds from advances payable - 100,000
Proceeds from issuance of convertible notes payable 245,000 2,422,250
Proceeds from issuance of convertible notes payable - related party 1,000,000 -
Proceeds from issuance of notes payable - 100,000 168,094 -
Proceeds from issuance of convertible notes payable 3,797,820 1,572,500
Proceeds from issuance of Series A Preferred Stock - 728,347
Repayment of financing liability (195,919 ) -
Repayment of notes payable (203,088 ) (200,000 ) (146,912 ) (199,588 )
Repayment of convertible notes payable (125,000 ) (146,000 ) - (125,000 )
Repayment of advances payable - (110,000 )
Repayment of financing liability (27,926 ) -
Net Cash Provided By Financing Activities 3,273,813 2,044,847 1,238,256 2,097,662

Net Increase In Cash and Restricted Cash 354,335 26,828

Cash and Restricted Cash - Beginning of Period 245,119 27,908

Cash and Restricted Cash - End of Period $ 599,454 $ 54,736
Net Decrease In Cash (90,498 ) (159,914 )
Cash - Beginning of Period 93,095 245,119
Cash - End of Period $ 2,597 $ 85,205

Cash and restricted cash consisted of the following:
Cash $ 599,454 $ 54,736 $ 2,597 $ 81,705
Restricted cash - - - 3,500
Cash and Restricted cash $ 599,454 $ 54,736
$ 2,597 $ 85,205
Supplemental Disclosures of Cash Flow Information:
Cash paid for:
Interest $ - $ - $ - $ -
Income taxes $ - $ - $ - $ -

Non-cash investing and financing activities:
Original issue discount in connection with convertible note payable $ - $ 58,556
Common stock issued in connection with payment of Series A Convertible Preferred Stock dividends in-kind $ 474,475 $ -
Conversion of convertible notes payable and accrued interest into Series C Preferred Stock and common stock $ 1,316,158 $ -
Reclassification of derivative liabilities to equity $ - $ 345,830
Conversion of Series C Convertible Preferred Stock into common stock $ 50 $ -
Accrual of earned preferred stock dividends $ (569,888 ) $ (449,264 )
Common stock issued in connection with payment of Series A and Series C Convertible Preferred Stock dividends in-kind $ 597,431 $ 474,475
Issuance of common stock pursuant to cashless warrant exercise $ 125 $ - $ - $ 125
Common stock issued in satisfaction of accrued compensation $ 7,097 $ -
Financing of Directors and Officer’s insurance $ 320,500 $ -
Accrued interest converted into notes payable $ 41,950 $ - $ - $ 41,950
Issuance of warrants in connection with the issuance of notes payable $ 461,269 $ - $ 57,262 $ 234,478
Accrual of warrant obligations in connection with issuance of notes payable $ 114,727 $ -
Issuance of warrants in satisfaction of accrued interest $ 247,566 $ 66,649 $ - $ 82,350
Accrual of earned preferred stock dividends $ (695,456 ) $ (649,381 )
Issuance of placement agent warrants $ - $ 10,907
Issuance of common stock as debt discount in in connection with extension of notes payable $ - $ 188,125
Repayment of convertible note payable and accrued interest by third party $ - $ 100,896
Warrants and conversion options issued in connection with issuance and extension of notes payable $ - $ 181,354
Warrants issued in connection with issuance of advance payable $ - $ 24,386
Conversion of convertible notes payable and accrued interest into Series C Preferred Stock and common stock $ 1,547,568 $ -

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

CELL SOURCE, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1 - Business Organization, Nature of Operations, Risks and Uncertainties and Basis of Presentation
Organization and Operations

Cell Source, Inc. (“Cell Source”, “CSI” or the “Company”) is a Nevada corporation formed on June 6, 2012 that is the parent company of Cell Source Limited (“CSL”), a wholly owned subsidiary which was founded in Israel in 2011 in order to commercialize a suite of inventions relating to certain cancer treatments. The Company is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The Company’s lead prospective product is its patented Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. CSL’s Veto Cell immune system management technology is based on technologies patented, owned, and licensed to CSL by Yeda Research and Development Company Limited, an Israeli corporation (“Yeda”) (see Note 8, Commitments and Contingencies). The Company’s target indications include: lymphoma, leukemia and multiple myeloma through the facilitation of ~~both~~ safer and more accessible stem cell (e.g. bone marrow) transplantation acceptance, ~~and effective allogeneic CAR-T cell therapy,~~ treatment of end stage kidney disease and other non-malignant organ diseases through improved organ transplantation (broadened donor pool, reduced dependence on post-transplant anti-rejection therapy), and ultimately treating a variety of cancers and non-malignant ~~diseases (e.g. sickle cell disease, diabetes).~~diseases.
Risks and Uncertainties

~~In March 2020, the World Health Organization declared COVID-19, a~~The novel ~~strain of~~ coronavirus ~~a pandemic. During 2020 and continuing into 2021, the global economy has been, and~~(“COVID-19”) pandemic continues to ~~be, affected by COVID-19. While the Company continues to see signs of~~impact global economic recovery as certain governments began to gradually ease restrictions, provide economic stimulus and vaccine distribution accelerated, the rate of recovery on a global basis has been affected by resurgence of the virus or its variants in certain jurisdictions causing reinstatement of restrictions in certain jurisdictions.conditions. The Company ~~continues to monitor~~is closely monitoring the ~~effects~~outbreak of COVID-19 and its impact on the Company’s operations, financial position, cash flows and its industry in general. The Company considered the impact of COVID-19 on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s condensed consolidated results of operations and financial position ~~at September~~as of June 30, ~~2021.~~2022.
~~The full extent of~~Similarly, the ~~future impact of~~economic uncertainty caused by the COVID-19 onpandemic has made and may continue to make it difficult for the ~~Company’s operations and financial condition is uncertain. Accordingly, COVID-19 could have a material adverse effect on the Company’s business,~~Company to forecast operating results, ~~of operations, financial condition and prospects during 2021 and beyond,~~ including the timing and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development. The ~~financial statements do not include any adjustments that might result~~duration and extent of the impact from the ~~outcome~~COVID-19 pandemic depend on future developments that cannot be accurately predicted at this time, and if the Company is not able to respond to and manage the impact of ~~this~~such events effectively, the Company’s business may be harmed. Additionally, other recent macroeconomic events including rising inflation, slowing economic growth, changes in U.S. and foreign government monetary policies, supply chain disruptions, fluctuations in currency exchange rates and the Russian invasion of Ukraine have led to further economic uncertainty. As a result, the Company is unable to predict the ultimate impact of other economic conditions and continuous presence of Covid-19 will have on its business, future results of operations, financial position, or cash flows.
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial position of the Company as of ~~September~~June 30, ~~2021~~2022 and the condensed consolidated results of its operations and cash flows for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020.~~2021. The results of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 are not necessarily indicative of the operating results for the full year ending December 31, ~~2021~~2022 or any other period. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, ~~2020~~2021 and for the year then ended which were included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on April 15, ~~2021.~~2022.
8
Note 2 - Going Concern and Management Plans
During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, the Company had not generated any revenues, had a net loss of approximately $~~4,637~~2,578,000 ~~,000~~ and had used cash in operations of approximately $1,329,000~~2,919,000~~. As of ~~September~~June 30, ~~2021,~~2022, the Company had a working capital deficiency of approximately $~~10,188,000~~10,767,000 and an accumulated deficit of approximately $~~30,343~~33,757,000~~,000.~~. As of June 30, 2022 and through the date of this filing, notes payable with principal amounts totaling $1,408,000 were past due and are classified as current liabilities on the condensed consolidated balance sheet as of June 30, 2022. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date these financial statements are issued. Subsequent to June 30, 2022 and as more fully described in Note 9, Subsequent Events, the Company received aggregate proceeds of $1,750,000 from the issuance of convertible notes payable and an additional advance under an outstanding convertible note.
8
The Company is currently funding its operations on a month-to-month basis. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. The Company’s primary sources of operating funds since inception have been equity and debt financings. Management’s plans include continued efforts to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, if the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.
The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.
Note 3 - Summary of Significant Accounting Policies
Since the date of the Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, there have been no material changes to the Company’s significant accounting policies.
Loss Per Share
The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share includes the dilution that would occur upon the exercise or conversion of all dilutive securities into common stock using the “treasury stock” and/or “if converted” methods, as applicable. ~~Weighted average shares outstanding for the three and nine months ended September 30, 2021 and 2020 includes the weighted average impact of warrants to purchase an aggregate of~~ 0 ~~and~~ ~~2,043,835~~ ~~shares, respectively, of common stock because their exercise price was determined to be nominal.~~
The common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
Schedule of Weighted Average Dilutive Common Shares ~~Anti-dilutive~~Anti-Dilutive
September 30, June 30,
2021 2020 2022 2021

Options 6,182,004 4,832,004 6,182,004 6,182,004
Warrants 11,201,946 6,250,676 12,284,079 9,946,388
Convertible notes [1] [2] 3,521,885 3,958,756
Convertible notes [1] [2] 1,951,241 1,760,041
Convertible preferred stock 15,054,910 13,421,950 18,123,043 13,421,950
Total 35,960,745 28,463,386 38,540,367 31,310,383
[1] Convertible notes are assumed to be converted at the rate of $0.75 per common share, which is the conversion price as of ~~September~~June 30, 2022 and 2021. However, such conversion rates are subject to adjustment under certain circumstances, which may result in the issuance of common shares greater than the amount indicated.
[2] Excludes shares of common stock underlying convertible notes that are expected to become convertible into shares of Series B Convertible Preferred Stock since such stock had not been designated by the Company as of ~~September~~June 30, 2022 and 2021.
9
Reclassifications

Certain prior period ~~balance sheet amounts~~balances have been reclassified in order to conform to ~~the fiscal 2021~~current year presentation. These reclassifications have no ~~impact~~effect on ~~the~~ previously reported ~~net loss.~~results of operations or loss per share.
9
~~Recently Issued Accounting Standards~~
On May 3, 2021, the Financial Accounting Standards Board (the “FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating this new standard and its impact on the Company’s condensed consolidated financial statements and related disclosures.
Note 4 - Fair Value
The following table provides a summary of the changes in fair value, including net transfers in and/or out, of all Level 3 liabilities measured at fair value on a recurring basis using unobservable inputs during the ~~nine~~three and six months ended ~~September~~June 30, 2022 and 2021:
Schedule of Changes in Fair Value of Liabilities Measured at Fair Value on a Recurring Basis
Accrued Accrued
Interest Compensation Total

Balance - January 1, 2021 $ 539,836 $ 84,953 $ 624,789

Change in fair value 41,607 97 41,704
Issuance of warrants (82,350 ) - (82,350 )

Balance - March 31, 2021 499,093 85,050 584,143

Change in fair value 37,994 (9 ) 37,985
Accrual of warrant obligation 164,857 - 164,857
Accrual of common stock obligation - 7,097 7,097

Balance - June 30, 2021 701,944 92,138 794,082

Change in fair value 39,012 20 39,032
Issuance of common stock - (7,097 ) (7,097 )
Issuance of warrants (165,216 ) - (165,216 )

Balance - September 30, 2021 $ 575,740 $ 85,061 $ 660,801
Accrued Accrued
Interest Compensation Total

Balance - January 1, 2022 $ 402,344 $ 61,306 $ 463,650

Change in fair value 33,609 (412 ) 33,197
Accrual of warrant obligation 114,727 - 114,727

Accrual of common stock obligation - 7,097 7,097

Balance - March 31, 2022 550,680 60,894 611,574

Change in fair value 29,658 74 29,732

Balance - June 30, 2022 $ 580,338 $ 60,968 $ 641,306
Accrued Accrued
Interest Compensation Total

Balance - January 1, 2021 $ 539,836 $ 84,953 $ 624,789

Change in fair value 41,607 97 41,704
Issuance of warrants (82,350 ) - (82,350 )

Balance - March 31, 2021 499,093 85,050 584,143

Change in fair value 37,994 (9 ) 37,985
Accrual of warrant obligation 164,857 - 164,857
Accrual of common stock obligation - 7,097 7,097

Balance - June 30, 2021 $ 701,944 $ 92,138 $ 794,082
Financial ~~liabilities~~assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the above table consist of accrued obligations to issue warrants and common stock.
In applying the Black-Scholes option pricing model utilized in the valuation of Level 3 liabilities, the Company used the following approximate assumptions:
Schedule of Assumptions Used for Valuation of Level 3 Liabilities
For the Three Months Ended For the Nine Months Ended For the Three Months Ended For the Six Months Ended
September 30, September 30, June 30, June 30,
2021 2020 2021 2020 2022 2021 2022 2021

Risk-free interest rate 0.28%-0.87 % 0.22% - 0.28 % 0.28%-0.92 % 0.15% - 1.55 % 3.00%-3.01 % 0.67%-0.87 % 2.42%-3.01 % 0.64%-0.92 %
Expected term (years) 4.00-5.00 4.00-5.00 4.00-5.00 0.52 - 5.00 4.00-5.00 4.00-5.00 4.00-5.00 4.00-5.00
Expected volatility 90 % 110 % 90 % 110 % 90 % 90 % 90 % 90 %
Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
The expected term used is the contractual life of the instrument being valued. Since the Company’s stock does not have significant trading volume, the Company is utilizing an expected volatility based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.
10
As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the Company had an obligation to issue 154,495 shares of common stock to service providers that had a fair value of $~~72,613~~52,528, which was a component of accrued compensation on the condensed consolidated balance sheets. Furthermore, as of June 30, 2022 and December 31, 2021, the Company has an obligation to issue warrants to purchase 42,930 shares of the Company’s common stock to service providers that had a fair value of $8,440 and $8,778, respectively.
See Note 6, Stockholders’ Deficiency – Common Stock and Stock Warrants for additional details associated with the issuance of common stock and warrants.
10
Note 5 – Notes Payable
As of ~~September~~June 30, ~~2021~~2022 and through the date of this filing, notes and convertible notes payable with principal amounts totaling $~~2,012,162~~ 1,408,000~~and $5,762,162,~~ ~~respectively,~~ were past due and are classified as current liabilities on the condensed consolidated balance sheet as of ~~September~~June 30, ~~2021.~~2022. Such notes continue to accrue interest and all relevant penalties have been accrued as of ~~September~~June 30, ~~2021.~~2022. Of such past due notes payable, a holder of a note with principal amount of $250,000issued a notice of default. See Note 8, Commitments and Contingencies – Litigation for additional details. The Company is in negotiations with ~~all~~certain holders of notes payable to extend the maturity dates of such notes or to convert the principal and accrued interest into equity.
During the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, the Company recorded interest expense of $~~214,431~~193,362 and $~~126,867~~162,845, respectively, and amortization of debt discount of $~~269,805~~58,355 and $~~146,109~~155,169, respectively. During the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, the Company recorded interest expense of $~~658,163~~360,127 and $~~308,395~~443,732, respectively, and amortization of debt discount of $~~547,737~~131,493 and $~~190,639~~277,932, respectively. As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the Company had $~~1,258,421~~1,574,021 and $~~997,244~~1,182,225, respectively, of accrued interest (including interest in the form of warrants (see Note 4)) and penalties related to notes payable, which is included with accrued interest and accrued interest – related parties on the condensed consolidated balance sheets.
Convertible Notes Payable
During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, the Company issued convertible notes payable in the aggregate principal amount of $~~2,297,947~~ 245,000which have maturity dates ranging from ~~July 7, 2021~~August 2, 2022 through ~~March 21,~~October 4, 2022. The notes accrue interest at 8% per annum and are convertible at any time at the option of the holder into the Company’s Series C Convertible Preferred Stock ~~(the “Series C Preferred Stock”)~~ at a conversion price of $7.50. per share. The notes automatically convert into Series C Convertible Preferred Stock on the maturity date. In connection with the issuances, the Company issued five-year immediately vested warrants to purchase an aggregate of ~~1,868,358~~ 176,000shares of common stock at an exercise price $1.25per share. The warrants had an issuance date relative fair value of $~~461,269~~ 25,448which will be amortized over the term of the notes. ~~A portion~~
During the six months ended June 30, 2022, an aggregate of ~~the~~$1,485,697 of principal outstanding under convertible notes ~~payable were (a)~~automatically converted ~~during nine months ended September 30, 2021 (see elsewhere in this Note for details)~~into an aggregate of 198,088 shares of Series C Convertible Preferred Stock and ~~(b) converted subsequent to September 30, 2021 (see Note 9 for details).~~
~~On January 28, 2021,~~ the Company ~~issued a convertible note payable in the amount~~elected to convert an aggregate of $~~647,222~~ ~~which matures on~~ ~~July 28, 2021~~61,871 ~~in exchange for another~~of interest accrued under such notes into an aggregate of 82,494 shares of common stock. The aggregate note ~~in the~~ principal ~~amount of $555,556~~ ~~that accrued interest at~~ 13~~% per annum and~~ had ~~accrued interest of $41,948. The new note accrues interest at~~ 8~~% per annum and such interest is payable at maturity, at the Company’s option, in cash or as payment-in-kind in common stock at~~ a ~~rate of $0.75~~ ~~per share.~~ ~~The note is convertible at the holder’s option into Series C Preferred Stock at a~~conversion price of $7.50 per share and ~~automatically converts into Series C Convertible Preferred Stock on~~ the ~~maturity date.~~ ~~In connection with the issuance of the convertible note, the Company issued a~~ ~~five-year immediately vested warrant to purchase~~ ~~517,778~~ ~~shares of common stock at an exercise price $1.25~~ ~~per share. The warrants had an issuance date fair value of $106,183~~ ~~that was recognized immediately. The Company determined the transaction was an extinguishment and, as a result, recognized a loss on extinguishment of notes payable of $49,718~~ on the condensed consolidated statement of operations during the nine months ended September 30, 2021. This convertible note payable was converted during the nine months ended September 30, 2021 (see elsewhere in this Note for details).
~~On March 2, 2021, the Company amended a previously issued convertible note in the principal amount of $2,000,000. In connection with this amendment, during the three months ended March 31, 2021, the Company (i) received further proceeds of $500,000, (ii) increased the principal amount from $2,000,000~~ ~~to $4,000,000~~ ~~and (iii) issued~~ ~~five-year immediately vested warrants for the purchase of~~ ~~800,000~~ ~~shares of common stock at an exercise price of $1.25~~ ~~per share, of which, warrants to purchase~~ ~~400,000~~ ~~shares of common stock were accrued for as December 31, 2020, and had an issuance date fair value of $164,700~~ ~~which will be amortized over the term of the note. On June 18, 2021, the Company amended and restated the note in the principal amount of $4,000,000. In connection with this amendment, during the three months ended June 30, 2021, the Company (i) received further proceeds of $1,000,000~~ ~~in connection with the note by means of the payment by the lender of outstanding obligations to third parties, (ii) increased the principal amount from $4,000,000~~ ~~to $6,000,000~~ ~~and (iii) agreed to issue a~~ ~~five-year immediately vested warrant to purchase~~ ~~800,000~~ ~~shares of common stock with an issuance date fair value of $164,857~~ ~~which will be amortized over the term of the note. The Company may elect to convert the amended and restated note into shares of Series B Convertible Preferred Stock at a conversion price of $7.50~~ ~~per share at any time after the creation of the Series B Convertible Preferred Stock and before the maturity date. As of September 30, 2021, an aggregate of $3,500,000~~ ~~of proceeds were outstanding under the note. The warrant to purchase~~ ~~800,000~~ ~~shares of~~ common stock was ~~issued during the three months ended September 30, 2021, such that the Company recognized the $165,216~~ ~~issuance date fair value by crediting additional paid-in capital.~~
~~On March 11, 2021, the Company entered into convertible note purchase agreements with two noteholders whereby the Company agreed to repurchase an aggregate of $125,000~~ ~~of convertible notes payable for the same amount in cash,~~valued at which time the notes were cancelled. In connection with the repayment, the parties agreed that the Company was no longer required to pay accrued interest associated with the notes payable in the amount of $~~49,983. As a result, the Company recognized a gain on forgiveness of accrued interest of $49,983~~ ~~on its condensed consolidated statement of operations during the nine months ended September 30, 2021.~~
11
~~On April 27, 2021, the Company amended the following terms of two convertible notes in the aggregate principal amount of $150,000: (i) the maturity dates were extended to~~ ~~October 15, 2021, (ii) the interest rate was amended from~~ 8~~% per annum to~~ 10% per annum and (iii) the shares into which the notes may be converted was amended from Series B Preferred Stock to Series C Preferred Stock. The Company determined the amendment represented a debt modification.
~~During the nine months ended September 30, 2021, convertible notes payable in the aggregate principal amount $1,262,222~~ ~~were converted into~~ ~~168,296~~ ~~shares of Series C Convertible Preferred Stock at an effective conversion price of $7.50~~ ~~per share. The Company elected to convert accrued interest on the same convertible notes payable in the aggregate amount of $53,936~~ ~~into~~ ~~71,915~~ ~~shares of common stock at an effective conversion price of~~ $0.75 per ~~share.~~
~~Through June 30, 2021,~~share for purposes of the Company had not designated the Series C Preferred Stock. As a result, the Company did not analyze the notes for a potential beneficial conversion feature as the definition of a firm commitment had not been met since the notes were not yet convertible. On July 26, 2021, the required Certificate of Designation was filed (see Note 6 – Stockholders’ Deficiency – Series C Convertible Preferred Stock). Accordingly, a firm commitment was achieved. interest payment. The Company analyzed the notes for a beneficial conversion feature and determined that there was none because the notes have an effective conversion price of $0.75per share of underlying common stock, which exceeds the $~~0.47~~ 0.34per share commitment date ~~closing market price~~ fair value of the common stock.
Convertible Notes Payable - Related Parties
On March 10, 2022, the Board of Directors of the Company appointed George Verstraete as a member of the Board.
The Company and Mr. Verstraete entered into a promissory note agreement dated March 10, 2022, whereby Mr. Verstraete, at his discretion, can loan up to $6,000,000 to the Company. Mr. Verstraete has agreed to loan an aggregate of $2,500,000 to the Company under the note. The note bears interest at a rate of 10% per annum and will mature twelve months from the date of issuance. Mr. Verstraete has the right, at his option, to convert the note into shares of the Company’s Series B Convertible Preferred Stock at a conversion price of $7.50 per share at any time after the creation and sale of the Series B Convertible Preferred Stock. Interest accruing under the note will be payable upon the maturity of the note and may be paid at the Company’s option in either cash or shares of the Company’s common stock (calculated based upon $0.75 per share for purposes of calculating the number of shares of common stock to be issued). For each $500,000 advanced under the note, Mr. Verstraete will be issued a warrant to purchase 400,000 shares of the Company’s common stock at an exercise price of $1.25 per share. Each warrant will have a five-year term. As of June 30, 2022, the Company had received $1,000,000 under the note. In connection with the issuance, the Company accrued an obligation to issue five-year immediately vested warrants to purchase an aggregate of 800,000 shares of common stock at an exercise price $1.25 per share. The warrants had an issuance date relative fair value of $114,727 which will be amortized over the term of the notes. Subsequent to June 30, 2022, the Company issued the 800,000 warrants which have been previously accrued for as of June 30, 2022. See Note 9, Subsequent Events- Convertible Notes Payable - Related Parties for additional details of an additional $1,500,000 advanced under the note subsequent to June 30, 2022.

11
Notes Payable
~~During the nine months ended September 30, 2021,~~On June 16, 2022, the Company ~~paid~~issued a note payable in the principal amount of $~~100,000~~168,094 which has a maturity date of June 16, 2023. The note accrues interest at 10% per annum and the interest shall be payable, at the Company’s election, either in cash or in common stock at $0.75 per share. In connection with the issuance, the Company issued a five-year immediately vested warrant to ~~a noteholder as a partial repayment~~purchase 200,000 shares of ~~principal such that~~common stock at an exercise price $0.75 per share. The warrants had an issuance date relative fair value of $31,814 which will be amortized over the ~~note had $150,000~~ ~~outstanding as~~term of ~~September 30, 2021 after~~ the ~~partial repayment.~~note.
See Note 8, Commitments and Contingencies – Litigation for details ~~associated with~~of the ~~partial~~ repayment of a certain note ~~payable during the nine months ended September 30, 2021.~~payable.
Note 6 – Stockholders’ Deficiency
Preferred Stock Dividends
During the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, the Company accrued additional preferred dividends ~~related to Series A and Series C Preferred Stock~~ of $~~246,192~~244,971 and $~~226,191~~225,873, respectively. During the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, the Company accrued additional preferred dividends ~~related to Series A and Series C Preferred Stock~~ of $~~695,456~~569,888 and $~~649,381~~449,264, respectively.
During the ~~nine~~three months ended ~~September~~June 30, ~~2021,~~2022, the Company issued ~~632,677~~796,629 shares of common stock at the stated value of $0.75 per share for aggregate value of $~~474,475~~597,431, pursuant to the terms of the Series A and C Convertible Preferred Stock Certificate of Designation, in connection with the partial payment of accrued dividends for Series A and C Convertible Preferred Stock.
Series C Convertible Preferred Stock

~~On July 26, 2021, the Company’s Board of Directors approved the designation of~~ ~~500,000~~ ~~shares~~ ~~of the~~ ~~10,000,000authorized~~ ~~shares of~~ ~~preferred stock as Series C Convertible Preferred Stock, par value $0.001~~ ~~per share. On July 26, 2021, the Company filed the Certificate of Designation with the State of Nevada related to the Series C Preferred Stock. The Series C Preferred stock has a stated value of $7.50~~ ~~per share.~~
~~Conversion.~~ Each share of Series C Preferred Stock is convertible into shares of common stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations) at the option of the holder at any time. The number of shares of common stock which are issuable upon conversion of the Series C Preferred Stock shall be equal to the number of shares of Series C Preferred Stock to be converted, multiplied by the stated value of $~~7.50~~ ~~per share, divided by the conversion price in effect at the time of conversion, initially at $0.75~~ ~~per share.~~
~~Mandatory Conversion.~~ On the earlier of (i) July 27, 2025 or (ii) any of the Company’s treatment candidates receiving approval from the U.S. or European agencies, all of the outstanding shares of Series C Preferred Stock will automatically convert to common stock.
~~Liquidation Preference.~~ In the event of the liquidation, dissolution or winding-up of the Company, the Series C Preferred Stock will rank senior to common stock and any other class of capital stock which does not expressly rank senior to or pari passu with the Series C Preferred Stock and will rank pari passu with the Series A and Series B Preferred Stock.
~~Voting Rights.~~The holders of Series C Preferred Stock have the right to vote on any matter submitted to a vote of holders of common stock, voting together with the common stock as one class, on an as-converted basis.
12
~~Dividends.~~~~Holders of shares of Series C Preferred Stock will be entitled to receive cumulative dividends at an annual rate of~~ 8% ~~of the stated value. Dividends are payable semi-annually on June 30 and December 31, commencing on December 31, 2022, either by (i) issuance of shares of common stock at the rate of $0.75 per share of common stock or (ii) in cash, at the Company’s option.~~
~~During the three months ended September 30, 2021,~~ ~~5,000~~ ~~shares of Series C Preferred Stock were converted into~~ ~~50,000~~ ~~shares of common stock at the shareholder’s election.~~ ~~The Company analyzed the Series C Preferred Stock for a beneficial conversion feature and determined that there was none because the Series C Preferred Stock has an effective conversion price of $0.75per share of underlying common stock, which exceeds the $0.47per share commitment date closing market price of the common stock.~~
~~See Note 5,~~ ~~Notes Payable – Convertible Notes Payable~~ ~~for details associated with note conversions.~~
~~Common Stock~~
~~During the nine months ended September 30, 2021, the Company issued~~ ~~5,405~~ ~~shares of immediately vested common stock to a service provided with a grant date fair value of $2,540~~ ~~which was recognized immediately.~~
~~During the three months ended September 30, 2021, the Company issued~~ ~~15,099~~ ~~shares of common stock to a consultant in satisfaction of accrued compensation with an issuance date fair value of $7,097~~.
~~During the three months ended September 30, 2021, the Company issued~~ ~~150,000~~ ~~shares of common stock to consultants which had an issuance date fair value of $70,500~~ ~~which was recognized immediately.~~
See Note 5, Notes Payable – Convertible Notes Payable for details associated with conversions of notes payable into 198,088 shares of Series C Convertible Preferred Stock.
Common Stock
See Note 5, Notes Payable – Convertible Notes Payable for details associated with conversions of accrued interest ~~conversions~~ into82,494 shares of common stock.

~~See elsewhere in this note,~~ ~~Stock Warrants~~ ~~for additional details.~~
Stock Warrants

~~On January 5, 2021, the Company issued~~ ~~125,000five-year immediately vested warrants to a note holder in satisfaction of certain noteholder rights with an exercise price $0.95~~ ~~per share. The warrant had an issuance date fair value of $33,545~~ ~~which was recognized immediately.~~
~~During the nine months ended September 30, 2021, the Company issued~~ ~~125,071~~ ~~shares of common stock pursuant to a cashless warrant exercise by a noteholder of warrants to purchase~~ ~~221,275~~ ~~shares of common stock at an exercise price of $0.75~~ ~~per share.~~
~~During the three months ended September 30, 2021, the Company issued~~ ~~125,000five-year immediately vested warrants to a consultant with an exercise price $0.75~~ ~~per share. The warrant had an issuance date fair value of $36,200~~ ~~which was recognized immediately.~~
~~In August 2021, the Company extended the expiration date of a warrant to purchase~~ ~~75,000~~ ~~shares of common stock at an exercise price of $0.75~~ ~~per share from August 4, 2021 to August 4, 2025 and extended the expiration date of a warrant to purchase~~ ~~37,500~~ ~~shares of common stock at an exercise price of $0.75~~ ~~per share from August 26, 2021 to August 26, 2025. The Company determined the transactions represented award modifications and recognized incremental expense of $29,000~~ ~~within interest expense on the condensed consolidated statement of operations during the three and nine months September 30, 2021.~~
See Note 5, Notes Payable for additional details associated with the issuance of stock warrants.

~~Stock Options~~
~~On March 8, 2021, the Company granted~~ ~~1,350,000five-year immediately vested options under the Company’s Equity Incentive Plan to the Chief Executive Offer of the Company (of which,~~ ~~750,000~~ ~~were granted for service as Chief Executive Officer and~~ ~~600,000~~ ~~were granted for service as a director) with an exercise price $1.00~~ ~~per share. The options had a grant date fair value of $218,600~~ ~~which was recognized during the nine months ended September 30, 2021.~~
Stock-Based Compensation
During the three months ended ~~September~~June 30, 2022, the Company recognized stock-based compensation expense of $(74) related to common stock which has been included within accrued compensation which was included within general and administrative expenses. During the three months ended June 30, 2021, the Company recognized stock-based compensation expense of $~~140,528~~45,972 (consisting of $~~70,028~~36,335 of expense related to warrants (of which, $~~70,009~~36,326 has been included within ~~stockholders’~~stockholder’s deficiency and $199 has been included within accrued compensation) and $~~70,500~~9,637 of expense related to common stock which has been included $7,097 within accrued compensation and $2,540 included within stockholder’s deficiency) which was included within general and administrative expenses.
13

During the ~~nine~~six months ended ~~September~~June 30, 2022, the Company recognized stock-based compensation expense of $5,034 (consisting of $5,372 of expense related to warrants and $(338) of expense related to common stock which has been included within accrued compensation) which was included within general and administrative expenses. During the six months ended June 30, 2021, the Company recognized stock-based compensation expense of $~~424,272~~283,744 (consisting of $~~137,735~~67,707 of expense related to warrants (of which, $~~137,628~~67,619 has been included within ~~stockholders’~~stockholder’s deficiency and $~~107~~88 has been included within accrued compensation), $206,400 of expense related to options which has been included within ~~stockholders’~~stockholder’s deficiency and $~~80,137~~9,637 of expense related to common stock which has been included $7,097 within accrued compensation and $2,540 included within ~~stockholders’~~stockholder’s deficiency) which was included within general and administrative expenses.
~~During the three and nine months ended September 30, 2020, the Company recognized stock-based compensation expense of $349,050~~ ~~and $686,472, respectively, related to common stock and warrants, which amounts were included within general and administrative expenses on the condensed consolidated statements of operations.~~

~~As of September 30, 2021, there~~There was $~~38,471~~no of unrecognized stock-based compensation expense ~~to be recognized over a weighted average period~~as of ~~0.24~~ ~~years.~~June 30, 2022.
12

Note 7 – Related Party Transactions

As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the Company was required to issue warrants to purchase an aggregate of ~~1,281,500~~1,506,500 and ~~1,056,500~~1,356,500, respectively, shares of common stock at an exercise price of $0.75 per share to directors of the Company in connection with loans made to the Company in the aggregate amount of $459,000 which required certain penalties in the form of warrants. As a result, the Company had accrued $~~359,314~~286,303 and $~~291,708~~249,389 associated with the fair value of the obligations as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively, which amount is included in accrued interest – related parties on the condensed consolidated balance sheets.
See Note 5, Notes Payable – Convertible Notes Payable – Related Parties for details of the issuance of a convertible note to a director of the Company.
Note 8 – Commitments and Contingencies
Yeda Research and License Agreement

During the three months ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, the Company recorded research and development expenses of approximately $~~12,500~~15,000 and $013,000, respectively, related to its Research and License Agreement with Yeda (the “Agreement”). During the ~~nine~~six months ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, the Company recorded research and development expenses of approximately $~~60,000~~29,000 and $~~112,000~~48,000, respectively, related to the Agreement. As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the Company had $~~39,419~~0 ~~and $136,919, respectively,~~ of accrued research and development expenses pursuant to the Agreement with ~~Yeda, which are included within current liabilities on the condensed consolidated balance sheets.~~Yeda.

MD Anderson Sponsored Research Agreements

The Company recognized $~~411,773~~ 429,505 and $~~and $237,546~~ 313,384of research and development expenses during the three months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, and $964,515~~925,921~~ and $~~600,017~~ 514,148of research and development expenses during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~ 2022 and ~~2020,~~2021, respectively, associated with services provided by The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) under the two agreements with MD Anderson dated November 2018 and February 2019, respectively. As of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, the Company had $~~211,009~~ 527,524and $~~462,785~~411,773, respectively, of accrued research and development expenses pursuant to the agreements with MD Anderson. Subsequent to ~~September~~June 30, ~~2021,~~2022, the Company and MD Anderson agreed to extend the Sponsored Research Agreement by one year to November 27, ~~2022.~~ 2023. Under the amendment, the research budget for the additional year is approximately $1,300,000.

Litigation

Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company, or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability and an estimate of the range of possible losses, if determinable and material, would be disclosed.
14
In January 2019, the holder of a promissory note in the principal amount of $250,000due on March 16, 2016instituted a collection action in the Supreme Court of the State of New York, County of New York. On June 12, 2019, the plaintiff served a motion for summary judgment through the Secretary of State which was heard on July 12, 2019 and granted. The Company contends that it was not given sufficient notice under the applicable statute and did not have an opportunity to oppose the motion. Judgment was entered in October 2019 in the amount of $267,680., which includes the principal amount due under the promissory note plus additional penalties and interest. The Company brought a motion to vacate based on the jurisdictional defect of the motion in not providing the required amount of time, but that motion was denied in February 2021 without properly addressing the jurisdictional issues raised by the Company. The Company has appealed the denial and then filed a motion to Renew and Reargue the motion to vacate based on the ~~Court's~~Court’s failure to address critical issues. That motion was also denied on April 15, 2021 without addressing the ~~Company's~~Company’s arguments. The Company ~~has~~ appealed both denials and the ~~second denial as well and is pursuing both appeals in a consolidated manner so as to resolve all issues together.~~ appeal was denied. While the ~~Company's~~Company’s motions were pending, the plaintiff has commenced steps to collect judgment. During the ~~nine months~~year ended ~~September 30,~~December 31, 2021, $103,088was released to an officer of the court and has been accounted for as partial note repayment, ~~such that, as~~with the balance of ~~September 30, 2021, there was~~the note of $146,912 ~~outstanding under~~repaid during the ~~note.~~ three months ended June 30, 2022. During the ~~nine months~~year ended ~~September 30,~~December 31, 2021, a third party, on behalf of the Company, ~~a third party~~ deposited the ~~full amount of the~~remaining unpaid ~~judgment~~judgement with the court, ~~which created an automatic stay of enforcement of this matter and~~ which will be used to resolve the underlying ~~note in the event of an adverse outcome on appeal.~~note.

Loss contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed. There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows. AsAside from the matters discussed above in this note and Note 9, Subsequent Events- Litigation, there are no other known contingencies through the date of ~~September 30, 2021 and December 31, 2020, the Company had not accrued any amounts for contingencies.~~this filing.

Note 9 – Subsequent Events

The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.
13
~~Series C Preferred Stock Conversion~~Convertible Notes Payable - Related Parties

~~In October 2021,~~Subsequent to June 30, 2022, Mr. Verstraete advanced the Company an additional $1,500,000 under a ~~holder~~convertible promissory note dated March 10, 2022. See Note 5, Notes Payable – Convertible Notes Payable – Related Parties for additional details. The Company also issued five-year immediately vested warrants to purchase an aggregate of ~~Series C Preferred Stock elected to convert~~ ~~10,000~~ ~~of such shares into~~ ~~100,000~~800,000 shares of common ~~stock.~~stock at an exercise price $1.25 per share.
Additionally, subsequent to June 30, 2022, the Company and Darlene Soave, a Director of the Company, entered into an agreement to amend a previously issued convertible note dated October 28, 2019 in the aggregate principal amount of up to $6,000,000, whereby the maturity date of the note was extended from October 28, 2022 to April 28, 2023.

Convertible Notes Payable ~~Conversions~~- Issuances
Subsequent to June 30, 2022, the Company issued convertible notes payable in the aggregate principal amount of $250,000 which have maturity dates ranging from December 31, 2022 through June 1, 2023. The notes accrue interest at 8% per annum and are convertible at any time at the option of the holder into the Company’s Series C Convertible Preferred Stock at a conversion price of $7.50 per share. The notes automatically convert into Series C Convertible Preferred Stock on the maturity date. In connection with the issuances, the Company issued five-year immediately vested warrants to purchase an aggregate of 200,000 shares of common stock at an exercise price $1.25 per share.

~~In November 2021,~~Convertible Notes Payable - Conversions
Subsequent to June 30, 2022, an aggregate of $~~557,250~~245,000 of principal outstanding under convertible notes automatically converted into an aggregate of ~~82,060~~32,667 shares of Series C Convertible Preferred Stock at a conversion price of $7.50 per share and the Company elected to pay an aggregate of $~~26,233~~9,540 of interest accrued under such notes by the issuance of an aggregate of ~~34,976~~12,720 shares of common ~~stock. The aggregate note principal had a conversion price of $7.50~~ ~~per share and the common~~ stock ~~was valued~~ at $0.75 per ~~share for purposes of the interest payment.~~share.

~~See Note 5,~~ ~~Notes Payable~~ Litigation~~for details associated with past due notes.~~
In August 2022, a holder of 360,000 shares of the Company’s common stock filed a complaint against the Company, its President and legal counsel in the United States District Court, Southern District of New York, claiming unspecified damages for an alleged wrongful refusal to authorize the Company’s transfer agent to remove restrictive legends from the shares held by the shareholder. The Company has filed a motion to dismiss the complaint which is pending. The complaint against the Company’s legal counsel was dismissed by the Court and the Company’s President has not been served.

Stock ~~Warrants~~Options
~~In November 2021, in connection with the conversion of a certain convertible note payable in the principal amount of $50,000~~,Subsequent to June 30, 2022, the Company ~~issued a~~granted five-year immediately vested ~~warrant~~stock options to purchase an aggregate of ~~144,290~~750,000 shares of ~~the Company’s~~ common stock at an exercise price of $~~1.25~~1.00 per ~~share.~~share to two directors of the Company.
1514

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of the condensed consolidated results of operations and financial condition of Cell Source, Inc. (“CSI”, “Cell Source”, the “Company”, “us,” “we,” “our,”) as of ~~September~~June 30, ~~2021~~2022 and for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 should be read in conjunction with our unaudited financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 as filed with the Securities and Exchange Commission (“SEC”) on April 15, ~~2021.~~2022.

This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words “may,” “will,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions, are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based. Factors that may affect our results include, but are not limited to, the risks and uncertainties discussed in Item 1A (“Risk Factors”) of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, filed with the SEC on April 15, ~~2021.~~2022.

Overview
We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology licensed from Yeda Research & Development Company Limited (“Yeda”), the commercial arm of the Weizmann Institute. We have since shifted the focus of our research and development efforts to MD Anderson.

This technology addresses one of the most fundamental challenges within human immunology: how to tune the immune response such that it tolerates selected desirable foreign cells, but continues to attack all other (undesirable) targets. In simpler terms, a number of potentially life-saving treatments have limited effectiveness today because the patient’s immune system rejects them. For example, while HSCT - hematopoietic stem cell transplantation (e.g. bone marrow transplantation) has become a preferred therapeutic approach for treating blood cell cancer, most patients do not have a matched family donor. Although matched unrelated donors and cord blood can each provide an option for such patients, haploidentical stem cell transplants (sourced from partially mismatched family members) are rapidly gaining favor as a treatment of choice. This is still a risky and difficult procedure primarily because of potential conflicts between host (recipient) and donor immune systems and also due to viral infections that often follow even successful HSCT while the compromised new immune system works to reconstitute itself by using the transplanted stem cells. Today, rejection is partially overcome using aggressive immune suppression treatments that leave the patient exposed to many dangers by compromising their immune system.

The unique advantage of Cell Source technology lies in the ability to induce sustained tolerance of transplanted cells (or organs) by the recipient’s immune system in a setting that requires only mild immune suppression, while avoiding the most common post-transplant complications. The scientific term for the result of successfully inducing such tolerance in a transplantation setting is chimerism, where the recipient’s immune system tolerates the co-existence of the (genetically different) donor type and host type cells. Attaining sustained chimerism is an important prerequisite to achieving the intrinsic GvL (graft versus leukemia) effect of HSCT and supporting the reconstitution of normal hematopoiesis (generation of blood cells, including those that protect healthy patients from cancer) in blood cancer patients. Preclinical data and initial clinical data show that Cell Source’s Veto Cell technology can provide superior results in allogeneic (donor-derived) HSCT by allowing for haploidentical stem cell transplants under a mild conditioning regimen, while avoiding the most common post-transplant complications. Combining this with CAR (Chimeric Antigen Receptor) T cell therapy as a unified VETO CAR-T treatment, we will be able to treat patients in relapse as well as those in remission and use the cancer killing power of CAR-T to protect the patient while their immune system fully reconstitutes, thus providing an end-to-end solution for blood cancer treatment by potentially delivering a fundamentally safer and more effective allogeneic HSCT: prevention of relapse; avoidance GvHD; prevention of viral infections; and enhanced persistence of GvL effect. This means that the majority of patients will be able to find a donor, and will have access to a potentially safer procedure with higher long term survival rates than what either donor-derived HSCT or autologous CAR-T each on their own currently provide.

15
The ability to induce permanent chimerism (and thus sustained tolerance) in patients – which allows the transplantation to overcome rejection without having to compromise the rest of the immune system - may open the door to effective treatment of a number of severe medical conditions, in addition to blood cancers, which are characterized by this need. These include:

● The broader set of cancers, including solid tumors, that can potentially be treated effectively using genetically modified cells such as CAR-T cell therapy, but also face efficacy and economic constraints due to limited persistence based on immune system issues (i.e., the need to be able to safely and efficiently deliver allogeneic CAR-T therapy). Inducing sustained tolerance to CAR-T cells may bring reduced cost and increased efficacy by allowing for off-the-shelf (vs. patient-derived) treatments with more persistent cancer killing capability.

16
● Organ failure and transplantation. A variety of conditions can be treated by the transplantation of vital organs. However, transplantation is limited both by the insufficient supply of available donor organs and the need for lifelong, daily anti-rejection treatments post-transplant. Haploidentical organ transplants, with sustained chimerism, have the potential to make life saving transplants accessible to the majority of patients, with the prospect of improved life quality and expectancy.

● Non-malignant hematological conditions (such as type one diabetes and sickle cell anemia) which could, in many cases, also be more effectively treated by stem cell transplantation if the procedure could be made safer and more accessible by inducing sustained tolerance in the stem cell transplant recipient.

Human Capital Resources
Other than our Chief Executive Officer, we currently do not have any full-time employees, but retain the services of independent contractors/consultants on a contract-employment basis.

Recent Developments

Preclinical Results and Clinical Results

After two years of intensive collaboration with Professor Zelig Eshhar, the inventor of CAR-T cell therapy, data confirmed that Veto Cells can markedly extend persistence of genetically modified T cells from the same donor and that genetically modified Veto Cells can effectively inhibit tumors expressing an antigen recognized by the transgenic T cell receptor. Furthermore, human Veto Cells transfected with CAR exhibit anti-tumor activity in-vitro without losing their veto activity. These preclinical results form the basis of our current development of a clinical protocol for allogeneic VETO CAR-T HSCT combined therapy for blood cancer treatment. Cell Source plans to submit this protocol for approval in ~~2022.~~2023. The Phase 1/2 clinical trial at the University of Texas MD Anderson Cancer Center, using Cell Source’s Anti-viral Veto Cells, has successfully completed the first treatment cohort, with 3 patients each receiving a haploidentical HSCT under reduced intensity conditioning with Veto Cells. This first in human dose optimization trial has thus far shown that the initial dose is in fact the optimal dose, as all three patients had successful stem cell engraftment after 42 days, in the absence of GvHD. Cell Source ~~is now continuing~~has continued the trial, ~~as it~~which proceeds with ~~the~~ subsequent cohorts of patients, ~~using~~and plans to present additional patient data at the ~~same dose level.~~
~~COVID-19~~American Society of Hematology Annual Meeting in December, 2022.

~~Recently, the outbreak of the novel coronavirus, or~~ COVID-19 ~~around the world has adversely impacted global commercial activity~~ and contributed to significant volatility in financial markets and disrupted normal business operations. The global impact of the outbreak has been rapidly evolving, and many countries have reacted by instituting quarantines and restrictions on travel, and many businesses and other institutions have temporarily closed or reduced work activities at their facilities. Such actions are creating disruption in global supply chains, and adversely impacting a number of industries, such as transportation, hospitality and entertainment. The outbreak could have a continued adverse impact on economic and market conditions and trigger a period of global economic slowdown. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of the novel coronavirus. Nevertheless, the novel coronavirus presents material uncertainty and its disruption of the capital markets may have a material adverse impact on our ability to raise additional capital and may slow down the pace at which research and clinical trials may be conducted on our behalf.Other Events

~~Designation~~The novel coronavirus (“COVID-19”) pandemic continues to impact global economic conditions. The Company is closely monitoring the outbreak of ~~Series C Convertible Preferred Stock~~COVID-19 and its impact on the Company’s operations, financial position, cash flows and its industry in general. The Company considered the impact of COVID-19 on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s condensed consolidated results of operations and financial position as of June 30, 2022.

~~On July 26, 2021,~~Similarly, the ~~Company’s Board of Directors approved~~economic uncertainty caused by the ~~designation of 500,000 shares~~ ~~of the 10,000,000~~ ~~authorized~~ ~~shares of~~ ~~preferred stock as Series C Convertible Preferred Stock, par value $0.001 per share. On July 26, 2021,~~COVID-19 pandemic has made and may continue to make it difficult for the Company ~~filed~~to forecast operating results, including the ~~Certificate of Designation with the State of Nevada related to the Series C Preferred Stock. The Series C Preferred stock has a stated value of $7.50 per share.~~
~~Conversion.~~ ~~Each share of Series C Preferred Stock is convertible into shares of common stock (subject to adjustment as provided in the related certificate of designation of preferences, rights~~timing and limitations) at the option of the holder at any time. The number of shares of common stock which are issuable upon conversion of the Series C Preferred Stock shall be equal to the number of shares of Series C Preferred Stock to be converted, multiplied by the stated value of $7.50 per share, divided by the conversion price in effect at the time of conversion, initially at $0.75 per share.
~~Mandatory Conversion.~~ On the earlier of (i) July 26, 2025 or (ii) any of the Company’s treatment candidates receiving approval from the U.S. or European agencies, all of the outstanding shares of Series C Preferred Stock will automatically convert to common stock.
17
~~Liquidation Preference.~~ ~~In the event of the liquidation, dissolution or winding-up~~ability of the Company ~~holders of Series C Preferred Stock will rank senior~~ to ~~common stock~~initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development. The duration and ~~any other class of capital stock which does not expressly rank senior to or pari passu with the Series C Preferred Stock and will rank pari passu with the Series A and Series B Preferred Stock.~~
~~Voting Rights.~~ The holders of Series C Preferred Stock have the right to vote on any matter submitted to a vote of holders of common stock, voting together with the common stock as one class, on an as-converted basis.
~~Dividends.~~ ~~Holders of shares of Series C Preferred Stock will be entitled to receive cumulative dividends at an annual rate of 8%~~extent of the ~~stated value. Dividends are payable semi-annually~~impact from the COVID-19 pandemic depend on ~~June 30~~future developments that cannot be accurately predicted at this time, and ~~December 31, commencing~~if the Company is not able to respond to and manage the impact of such events effectively, the Company’s business may be harmed. Additionally, other recent macroeconomic events including rising inflation, slowing economic growth, changes in U.S. and foreign government monetary policies, supply chain disruptions, fluctuations in currency exchange rates and the Russian invasion of Ukraine have led to further economic uncertainty. As a result, the Company is unable to predict the ultimate impact of other economic conditions and continuous presence of Covid-19 will have on ~~December 31, 2022, either by (i) issuance~~its business, future results of ~~shares of common stock at the rate of $0.75 per share of common stock~~operations, financial position, or ~~(ii) in cash.~~cash flows.
16
Condensed Consolidated Results of Operations
Three Months Ended ~~September~~June 30, ~~2021~~2022 Compared with the Three Months Ended ~~September~~June 30, ~~2020~~2021
Research and Development
Research and development expense was $569,510 and $367,551 for the three months ended June 30, 2022 and 2021, respectively, an increase of $201,959, or 55%. This increase is primarily attributable to increased quarterly payments to $324,000 during the 2022 period as compared to $200,764 during the 2021 period under the sponsored research agreement with MD Andersen, a difference of $123,236. Furthermore, we enrolled additional patients during the 2022 period which resulted in research and development expense of $211,010 being recognized during the 2022 period compared to $112,620 during the 2021 period.
General and Administrative
General and administrative expense, which is associated with external consulting and professional fees, payroll and stock-based compensation expenses, was $464,367 and $627,548 for the three months ended June 30, 2022 and 2021, respectively, a decrease of $163,181, or 26%. The decrease was primarily attributable to a reduction in consulting fees of $94,000, stock-based compensation of $45,897 and a reduction of expenses related to exchange rate differences of $19,967 during the 2022 period.
Interest Expense
Interest expense for the three months ended June 30, 2022 and 2021 was $193,362 and $162,845, respectively, an increase of $30,517, or 19%. The increase was due to more interest-bearing notes outstanding during the period.
Amortization of Debt Discount
Amortization of debt discount was $58,355 and $155,169 for the three months ended June 30, 2022 and 2021, respectively, a decrease of $96,814, or 62%. This decrease is primarily associated with a decreased amount and fair value of warrants issued in connection with convertible notes payable during the 2022 period.
Six Months Ended June 30, 2021 Compared with the Six Months Ended June 30, 2021

Research and Development
Research and development expense was ~~$459,273~~$1,048,515 and ~~$257,546~~$638,790 for the ~~three~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, an increase of ~~$201,727,~~$409,725, or ~~78%~~64%. ~~The~~This increase ~~was primarily~~is attributable to ~~a clinical trial milestone reached~~increased payments of $648,000 (quarterly payments of $324,000) during the ~~third quarter~~2022 period as compared to $401,528 (quarterly payments of $200,764) during the 2021 period under the sponsored research agreement with MD Andersen, a difference of $246,472. Furthermore, we enrolled additional patients during the 2022 period which resulted in ~~additional~~research and development expense of $316,515 being recognized ~~related~~during the 2022 period compared to ~~our agreement with MD Anderson.~~
$112,620 during the 2021 period.

General and Administrative

General and administrative expense, which is associated with external consulting and professional fees, payroll and stock-based compensation expenses, was ~~$856,059~~$1,038,034 and ~~$908,099~~$1,477,665 for the ~~three~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, a decrease of ~~$52,040,~~$439,631, or 6%30%. ~~Such~~The decrease was primarily attributable to ~~decreased professional~~a reduction in consulting expenses of $247,845, a decrease in stock-based compensation of $278,709, this was partially offset by an increase in legal fees ~~during the 2021 period.~~of $133,256.

Interest Expense

Interest expense for the ~~three~~six months ended ~~September~~June 30, 2022 and 2021 was $360,127 and ~~2020 was $214,431 and $126,867,~~$443,732, respectively, ~~an increase~~a decrease of ~~$87,564,~~$83,605, or ~~69%~~19%. The ~~increase~~decrease was primarily a result of ~~increases~~decreases in convertible notes payable outstanding during the ~~2021~~2022 period as well as the fair value of warrants issued as interest.

Amortization of Debt Discount

Amortization of debt discount was ~~$269,805~~$131,493 and ~~$146,109~~$277,932 for the ~~three~~six months ended ~~September~~June 30, 2022 and 2021, ~~and 2020,~~ respectively, ~~an increase~~a decrease of ~~$123,696,~~$146,439, or ~~85%~~53%. The ~~increase~~decrease is primarily associated with ~~increased~~the decreased levels of warrants and common stock issued as debt discounts in connection with convertible notes payable in the ~~2021~~2022 period.

~~Loss on Exchange of Accrued Interest for Common Stock~~
During the three months ended September 30, 2021 and 2020, we recognized $0 and $132,502 of loss on extinguishment of notes payable which represents the excess carrying value of the $199,151 of accrued interest as compared to the issuance date fair value of the common stock of $66,649.
~~Loss on Extinguishment of Notes Payable~~
~~During the three months ended September 30, 2021 and 2020, we recognized $0 and $1,511 of loss on extinguishment of notes payable in connection with the extension and repayment of notes payable.~~
~~Nine Months Ended September 30, 2021 Compared with the Nine Months Ended September 30, 2020~~
~~Research and Development~~
Research and development expense was $1,098,063 and $786,684 for the nine months ended September 30, 2021 and 2020, respectively, an increase of $311,379, or 40%. The increase was primarily attributable to a clinical trial milestone reached during the second and third quarters of 2021 which resulted in additional expense recognized related to our agreement with MD Anderson as well as an increase in the budget for sponsored research there.
1817
~~General and Administrative~~
General and administrative expense, which is associated with external consulting and professional fees, payroll and stock-based compensation expenses, was $2,333,724 and $2,015,624 for the nine months ended September 30, 2021 and 2020, respectively, an increase of $318,100, or 16%. The increase was primarily related to additional expenses recognized in the 2021 period as follows: approximately $97,000 of accounting fees, approximately $396,000 of legal and consulting fees, approximately $82,000 of insurance expenses, partially offset by a decrease of approximately $262,000 in stock based compensation.
~~Interest Expense~~
Interest expense for the nine months ended September 30, 2021 and 2020 was $658,163 and $308,395, respectively, an increase of $349,768, or 113%. The increase was primarily a result of increases in convertible notes payable outstanding during the 2021 period as well as the fair value of warrants issued as interest.
~~Amortization of Debt Discount~~
Amortization of debt discount was $547,737 and $190,639 for the nine months ended September 30, 2021 and 2020, respectively, an increase of $357,098, or 187%. The increase is primarily associated with increased levels of warrants and common stock issued as debt discounts in connection with convertible notes payable in the 2021 period.

Gain on Forgiveness of Accrued Interest

During the ~~nine~~six months ended ~~September~~June 30, 2021, we recognized a gain on forgiveness of accrued interest of $49,983 in connection with the repayment of certain notes payable.

~~Gain on Exchange of Accrued Interest for Common Stock~~
During the nine months ended September 30, 2020, we recognized a $132,502 gain on exchange of accrued interest for common stock which represents the excess carrying value of the $199,151 of accrued interest as compared to the issuance date fair value of the common stock of $66,649.
~~Change in Fair Value of Derivative Liabilities~~
The change in fair value of derivative liabilities for the nine months ended September 30, 2020 was a gain of $16,977 due to the reduction in fair value of warrants and conversion options as a result of drawing closer to their expiration dates.
Loss on Extinguishment of Notes Payable

During the ~~nine~~six months ended ~~September~~June 30, 2021, ~~and 2020,~~ we recognized ~~$49,718 and $134,202 of~~a loss on extinguishment of notes payable ~~in connection with the extension and repayment~~ of ~~notes payable.~~$49,718.

Liquidity and Going Concern

We measure our liquidity in a number of ways, including the following:

September 30, 2021 December 31, 2020 June 30,
2022 December 31,
2021

Cash $ 599,454 $ 241,619 $ 2,597 $ 93,095
Restricted cash $ - $ 3,500
Working capital deficiency $ (10,187,899 ) $ (7,950,882 ) $ (10,766,559 ) $ (9,826,135 )
During the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, we had not generated any revenues, had a net loss of approximately ~~$4,637,000~~$2,578,000 and had used cash in operations of approximately ~~$2,919,000.~~$1,329,000. As of ~~September~~June 30, ~~2021,~~2022, we had a working capital deficiency of approximately ~~$10,188,000~~$10,767,000 and an accumulated deficit of approximately ~~$30,343,000.~~$33,757,000. As of June 30, 2022 and through the date of this filing, notes and convertible notes payable with principal amounts totaling $1,408,000 were past due and are classified as current liabilities on the condensed consolidated balance sheet as of June 30, 2022. These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date these financial statements are issued. Subsequent to June 30, 2022, we received aggregate proceeds of $1,750,000 from the issuance of convertible notes payable.

We are currently funding our operations on a month-to-month basis. Our ability to continue our operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. We may need to incur additional liabilities with certain related parties to sustain our existence. If we were not to continue as a going concern, we would likely not be able to realize our assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of our financial statements.

There can be no assurances that we will be successful in generating additional cash from equity or debt financings or other sources to be used for operations. Should we not be successful in obtaining the necessary financing to fund our operations, we would need to curtail certain or all operational activities and/or contemplate the sale of our assets, if necessary.

19
During the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, and ~~2020,~~2021, our sources and uses of cash were as follows:

Net Cash Used in Operating Activities
We experienced negative cash flows from operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, and ~~2020~~2021 in the amounts of approximately ~~$2,919,000~~$1,329,000 and ~~$2,018,000,~~$2,258,000, respectively. The net cash used in operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, was primarily due to cash used to fund a net loss of approximately ~~$4,637,000,~~$2,578,000, adjusted for ~~net~~ non-cash expenses in the aggregate amount of approximately ~~$1,258,000,~~$200,000, partially offset by $~~460,000~~1,050,000 of net cash provided by changes in the levels of operating assets and liabilities. The net cash used in operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021, was primarily due to cash used to fund a net loss of approximately ~~$3,286,000,~~$2,838,000, adjusted for net non-cash expenses in the aggregate amount of approximately ~~$923,000, partially offset by $345,000~~$780,000, and $200,000 of net cash ~~provided by~~used in changes in the levels of operating assets and liabilities.
Net Cash Provided by Financing Activities
Net cash provided by financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, and ~~2020~~2021 was approximately ~~$3,274,000~~$1,238,000 and ~~$2,045,000,~~$2,098,000, respectively. The net cash provided by financing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, was attributable to ~~$3,797,820~~$1,000,000 of proceeds from the issuance of convertible notes to a related party director and $245,000 of proceeds from the issuance of convertible notes payable, proceeds from the issuance of notes payable of $168,000, partially offset by the repayments of ~~notes payable, convertible notes payable, and~~ the insurance financing liability in the amount of ~~$524,007.~~$28,000 and the repayment of notes payable of $147,000. The net cash provided by financing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021, was attributable to ~~$1,572,500~~approximately $2,422,000 of proceeds from the issuance of convertible notes payable, ~~$728,347 of proceeds from~~partially offset by the ~~issuance of Series A preferred stock, $100,000 of proceeds from the issuance~~repayments of notes payable and ~~$100,000 of proceeds from advances payable, offset by the repayment of a note~~convertible notes payable in the amount of ~~$200,000, $110,000 of repayments of advances payable and a $146,000 repayment of a convertible note payable.~~$325,000.
18

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.

Critical Accounting ~~Policies and~~ Estimates

The preparation of financial statements and related disclosures in conformity with U.S. GAAP. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which it relies are reasonably based upon information available to us at the time that it makes these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described below.

The following is not intended to be a comprehensive list of all of our accounting policies or estimates. Our accounting policies are more fully described in Note 3 – Summary of Significant Accounting Policies, in our financial statements included elsewhere in this quarterly report.

Convertible Instruments

The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument and are amortized as interest expense over the term of the related debt instrument.

If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.

20
The Black-Scholes option pricing model was used to estimate the fair value of the Company’s warrants and embedded conversion options. The Black-Scholes option pricing model includes subjective input assumptions that can materially affect the fair value estimates. ~~The Company determined the fair value under the Binomial Lattice model and the Black-Scholes option pricing model to be materially the same.~~
~~Embedded conversion options within notes payable are recorded as a debt discount and are amortized as interest expense over the term of the related debt instrument.~~

Fair Value of Financial Instruments

The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

The carrying amounts of the Company’s financial instruments, such as cash, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments. The carrying amounts of Company’s credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, are comparable to rates of returns for instruments of similar credit risk.
19

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the period the services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.

Because the Company’s common stock historically was not actively traded on a public market, the fair value of the Company’s restricted equity instruments is estimated by management based on observations of the sales prices of both restricted and freely tradable common stock, or instruments convertible into common ~~stock.~~stock based on the option pricing model discussed below. The Company obtained a third-party valuation of its common stock as of December 31, ~~2020,~~2021, which was considered and remains reasonable in management’s estimation of fair value during the ~~nine~~three and six months ended ~~September~~June 30, ~~2021.~~2022. The third-party valuation was performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The estimates used by management are considered highly complex and subjective. The Company anticipates that once its shares become more actively traded, the use of such estimates will no longer be necessary to determine the fair value of its common stock.

The ~~December 2020~~ independent ~~appraisal~~appraisals utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:
● Establishment of total enterprise or equity value;
● Analysis of equity rights for each class of security;
● Selection of appropriate model for valuation purposes;
● Determination of key valuation inputs; and
● Computation of the fair value of the subject security.

Under the OPM, it was determined the Company’s common stock had a fair value of ~~$0.47~~$0.34 per share as of December 31, 2021, which included a discount for lack of marketability of 30%. Furthermore, the independent appraisal determined the Company’s expected volatility was 90% by evaluating historical and implied volatilities of guideline companies. The Company evaluates the facts and circumstances regarding the valuation of its common stock and has determined that since nothing significant has changed since December 31, 2021, the fair value of $0.34 per share was still appropriate to be used as of June 30, 2022.
21
Item 3. Quantitative And Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Annual Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Principal Executive and Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Internal controls are procedures which are designed with the objective of providing reasonable assurance that (1) our transactions are properly authorized, recorded and reported; and (2) our assets are safeguarded against unauthorized or improper use, to permit the preparation of our condensed consolidated financial statements in conformity with United States generally accepted accounting principles.

In connection with the preparation of this Quarterly Report, management, with the participation of our Principal Executive and Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Principal Executive and Financial Officer concluded that, as of ~~September~~June 30, ~~2021,~~2022, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended ~~September~~June 30, ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
2220

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Except as described below, we are not involved in any pending legal proceeding or litigations and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on us.

In January 2019, the holder of a promissory note in the principal amount of $250,000 due on March 16, 2016 instituted a collection action in the Supreme Court of the State of New York, County of New York. On June 12, 2019, the plaintiff served a motion for summary judgment through the Secretary of State which was heard on July 12, 2019 and granted. The Company contends that it was not given sufficient notice under the applicable statute and did not have an opportunity to oppose the motion. Judgment was entered in October 2019 in the amount of ~~$267,680.~~$267,680, which includes the principal amount due under the promissory note plus additional penalties and interest. The Company brought a motion to vacate based on the jurisdictional defect of the motion in not providing the required amount of time, but that motion was denied in February 2021 without properly addressing the jurisdictional issues raised by the Company. The Company has appealed the denial and then filed a motion to Renew and Reargue the motion to vacate based on the ~~Court's~~Court’s failure to address critical issues. That motion was also denied on April 15, 2021 without addressing the ~~Company's~~Company’s arguments. The Company ~~has~~ appealed both denials and the ~~second denial as well and is pursuing both appeals in a consolidated manner so as to resolve all issues together.~~appeal was denied. While the ~~Company's~~Company’s motions were pending, the plaintiff has commenced steps to collect judgment. During the ~~nine months~~year ended ~~September 30,~~December 31, 2021, $103,088 was released to an officer of the court and has been accounted for as partial note repayment, ~~such that, as~~with the balance of ~~September 30, 2021, there was~~the note of $146,912 ~~outstanding under~~released to an officer of the ~~note. During~~court during the ~~nine~~three months ended ~~September~~June 30, ~~2021, on behalf~~2022, which was also accounted for as a note repayment.
In August 2022, a holder of 360,000 shares of the Company’s common stock filed a complaint against the Company, ~~a third party deposited the full amount of the unpaid judgment with the court, which created an automatic stay of enforcement of this matter~~its President and ~~which will be used to resolve the underlying note~~legal counsel in the ~~event~~United States District Court, Southern District of New York, claiming unspecified damages for an ~~adverse outcome on appeal.~~alleged wrongful refusal to authorize the Company’s transfer agent to remove restrictive legends from the shares held by the shareholder. The Company has filed a motion to dismiss the complaint which is pending. The complaint against the Company’s legal counsel was dismissed by the Court and the Company’s President has not been served.

Item 1A. Risk Factors.

There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, which was filed with the SEC on April 15, ~~2021.~~2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

~~In August 2021, we issued a five-year warrant to purchase a total of 800,000 shares of common stock at an exercise price of $1.25 per share to a lender in accordance with~~During the ~~terms of a convertible note. We relied upon the exemptions provided by Section 4(2) of the Securities Act in connection with this transaction.~~
~~From July 26, 2021 through November 2021,~~three months ended June 30, 2022 convertible notes in the aggregate principal amount of ~~$1,769,472~~$110,000 automatically converted into ~~235,929~~14,667 shares of our Series C Convertible Preferred Stock on the maturity dates of the convertible notes. ~~In August 2021, a holder of the Series C Preferred Stock elected to convert 5,000 of such shares into 50,000 shares of common stock.~~ We relied upon the exemption provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”) in connection with these transactions.

~~In July 2021,~~During the three months ended June 30, 2022 we issued an aggregate of ~~71,915~~5,965 shares of our common stock to holders of convertible notes in lieu of cash interest upon the maturity of the notes. We relied upon the exception provided by Section 4(2) of the Securities Act in connection with ~~this transaction.~~these transactions.

~~In August 2021,~~During the three months ended June 30, 2022, we issued convertible notes in the aggregate principal amount of $150,000 to three accredited investors. The notes mature six months from the date of issuance and accrue interest at a ~~five-year warrant~~rate of eight percent (8%) per annum. The notes are convertible into shares of our Series C Preferred Stock at a conversion price of $7.50 per share at the holder’s option beginning on the date we first issue any shares of Series C Preferred Stock and automatically on the maturity date. It is anticipated that the Series C Preferred Stock will convert into shares of our common stock at a rate of ten shares of common stock for each share of Series C Preferred Stock. In connection with the issuance of the notes, we issued five year warrants to purchase ~~125,000~~an aggregate of 120,000 shares of common stock at an exercise price of ~~$.75~~$1.25 per ~~share to a consultant.~~share. We relied upon the ~~exception~~exemption provided by Section 4(2) of the Securities Act in connection with these transactions.

In ~~August 2021,~~June 2022, we ~~extended the expiration date of~~issued a five-year warrant to purchase ~~150,000~~200,000 shares of our common stock at an exercise price of $0.75 per share ~~from August 4, 2021 to August 4, 2025 and extended~~in connection with the ~~expiration date~~issuance of a ~~warrant to purchase 37,500 shares~~note in the principal amount of ~~common stock at an exercise price of $0.75 per share from August 26, 2021 to August 26, 2025.~~$168,094. We relied upon the exemption ~~provided by Section 3(a)(9) of the Securities Act in connection with these transactions.~~
In October 2021, a holder of Series C Preferred Stock elected to convert 10,000 of such shares into 100,000 shares of common stock. We relied upon the exemption provided by Section 3(a)(9) of the Securities Act in connection with this transaction.
~~During the three months ended September 30, 2021, we issued 165,099 shares of common stock to consultants. We relied upon the exception~~ provided by Section 4(2) of the Securities Act in connection with these ~~transactions.~~transactions
In November 2021, we issued 14,429 shares of Series C Preferred Stock and a five-year warrant to purchase 144,290 shares of common stock at an exercise price of $1.25 per share in connection with the conversion of a convertible note in the principal amount of $50,000. We relied upon the exemption provided by Section 3(a)(9) of the Securities Act in connection with this transaction.
2321
Item 3. Defaults Upon Senior Securities.

As of ~~September~~June 30, ~~2021~~2022 and through the date of this filing, notes ~~payable~~ and convertible notes payable with ~~face values~~principal amounts totaling ~~$2,012,162 and $5,762,162, respectively,~~$1,408,000 were past due and are classified as current liabilities on the condensed consolidated balance sheet as of ~~September~~June 30, ~~2021.~~2022. Such notes continue to accrue interest and all relevant penalties have been accrued as of ~~September~~June 30, ~~2021.~~2022. Of such past due notes payable, a holder of a note with principal amount of $250,000 issued a notice of default. See Item 1 above for additional details. We are in negotiations with all holders to extend the maturity dates of such notes or to convert the principal and accrued interest into equity.

Item 4. Mine Safety Disclosures.

Not applicable.
Item 5. Other Information.

None.

Item 6. Exhibits.

10.39(b)* ~~Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited.~~
31* Certification of principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32* Certification of principal executive officer and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
* Filed herewith

2422

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELL SOURCE, INC.

Dated: ~~November 15, 2021~~December 2, 2022 By: /s/ Itamar Shimrat
Name: Itamar Shimrat
Title:
Chief Executive Officer and
Chief Financial Officer (Principal
Executive, Financial and Accounting
Officer)

2523


	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2021			2020			2021			2020

Operating Expenses:
Research and development	$	446,773		$	257,546		$	1,037,588		$	675,017
Research and development - related party		12,500			-			60,475			111,667
General and administrative		856,059			908,099			2,333,724			2,015,624
Total Operating Expenses		1,315,332			1,165,645			3,431,787			2,802,308
Loss From Operations		(1,315,332	)		(1,165,645	)		(3,431,787	)		(2,802,308	)

Other (Expense) Income:
Interest expense		(191,626	)		(114,040	)		(588,314	)		(271,687	)
Interest expense - related parties		(22,805	)		(12,827	)		(69,849	)		(36,708	)
Amortization of debt discount		(269,805	)		(146,109	)		(547,737	)		(190,639	)
Change in fair value of derivative liabilities		-			-			-			16,977
Gain on forgiveness of accrued interest		-			-			49,983			-
Gain on exchange of accrued interest for common stock		-			132,502			-			132,502
Loss on extinguishment of notes payable		-			(1,511	)		(49,718	)		(134,202	)
Total Other Expense		(484,236	)		(141,985	)		(1,205,635	)		(483,757	)
Net Loss		(1,799,568	)		(1,307,630	)		(4,637,422	)		(3,286,065	)
Dividend attributable to Series A and Series C preferred stockholders		(246,192	)		(226,191	)		(695,456	)		(649,381	)
Net Loss Applicable to Common Stockholders	$	(2,045,760	)	$	(1,533,821	)	$	(5,332,878	)	$	(3,935,446	)

Net Loss Per Common Share - Basic and Diluted	$	(0.06	)	$	(0.05	)	$	(0.16	)	$	(0.13	)

Weighted Average Common Shares Outstanding -
Basic and Diluted		33,461,141			31,846,661			32,897,010			30,334,852


	FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021
	Convertible Preferred				Convertible Preferred										Additional						Total
	Stock - Series A				Stock - Series C						Common Stock				Paid- In			Accumulated			Stockholders’
	Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			Deficiency

Balance, January 1, 2021		1,342,195	$	1,342		-		$	-			32,538,411	$	32,538	$	17,724,731		$	(25,705,993	)	$	(7,947,382	)
Series A Convertible Preferred Stock dividends:
Accrual of earned dividends		-		-		-			-			-		-		(223,391	)		-			(223,391	)
Payment of dividends in kind
Payment of dividends in kind, shares

Issuance of common stock pursuant to cashless warrant exercise		-		-		-			-			125,071		125		(125	)		-			-

Issuance of warrants in connection with issuance of convertible notes payable		-		-		-			-			-		-		196,966			-			196,966

Issuance of warrants in connection with exchange of convertible notes payable		-		-		-			-			-		-		139,728			-			139,728

Warrants issued in satisfaction of accrued interest		-		-		-			-			-		-		82,350			-			82,350

Stock-based compensation:
Common stock
Common stock, shares
Options		-		-		-			-			-		-		206,400			-			206,400
Warrants		-		-		-			-			-		-		31,276			-			31,276
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock
Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock, shares
Conversion of Series C Convertible Preferred Stock into common stock
Conversion of Series C Convertible Preferred Stock into common stock, shares
Warrants modification expense
Common stock issued in satisfaction of accrued compensation
Common stock issued in satisfaction of accrued compensation , shares
Issuance of common stock in connection with extension of notes payable
Issuance of common stock in connection with extension of notes payable, shares
Reclassification of derivative liabilities to equity
Issuance of warrants in connection with issuance of notes payable
Issuance of common stock in exchange of accrued interest
Issuance of common stock in exchange of accrued interest
Issuance of Series A Convertible Preferred Stock for cash
Issuance of Series A Convertible Preferred Stock for cash, shares
Issuance of warrants in connection with issuance of advance payable

Net loss		-		-		-			-			-		-		-			(1,524,741	)		(1,524,741	)

Balance, March 31, 2021		1,342,195		1,342		-			-			32,663,482		32,663		18,157,935			(27,230,734	)		(9,038,794	)

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends		-		-		-			-			-		-		(225,873	)		-			(225,873	)
Payment of dividends in kind		-		-		-			-			632,677		633		473,842			-			474,475

Issuance of warrants in connection with issuance of convertible notes payable		-		-		-			-			-		-		37,512			-			37,512

Stock-based compensation:
Common stock		-		-		-			-			5,405		5		2,535			-			2,540
Warrants		-		-		-			-			-		-		36,343			-			36,343

Net loss		-		-		-			-			-		-		-			(1,313,113	)		(1,313,113	)

Balance, June 30, 2021		1,342,195		1,342		-			-			33,301,564		33,301		18,482,294			(28,543,847	)		(10,026,910	)

Series A and C Convertible Preferred Stock dividends:
Accrual of earned dividends		-		-		-			-			-		-		(246,192	)		-			(246,192	)

Conversion of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock		-		-		168,296			168			71,915		72		1,315,918			-			1,316,158

Conversion of Series C Convertible Preferred Stock into common stock		-		-		(5,000	)		(5	)		50,000		50		(45	)		-			-

Warrants issued in satisfaction of accrued interest		-		-		-			-			-		-		165,216			-			165,216

Warrants modification expense		-		-		-			-			-		-		29,000			-			29,000

Common stock issued in satisfaction of accrued compensation		-		-		-			-			15,099		16		7,081			-			7,097

Issuance of warrants in connection with issuance of convertible notes payable		-		-		-			-			-		-		226,791			-			226,791

Stock-based compensation:
Common stock		-		-		-			-			150,000		150		70,350			-			70,500
Warrants		-		-		-			-			-		-		70,009			-			70,009

Net loss		-		-		-			-			-		-		-			(1,799,568	)		(1,799,568	)

Balance, September 30, 2021		1,342,195	$	1,342		163,296		$	163			33,588,578	$	33,589	$	20,120,422		$	(30,343,415	)	$	(10,187,899	)

								1
	FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020
	Convertible Preferred				Convertible Preferred								Additional						Total
	Stock - Series A				Stock - Series C				Common Stock				Paid- In			Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Deficiency

Balance, January 1, 2020		1,245,083	$	1,245		-		-		27,076,762	$	27,077	$	15,375,565		$	(21,145,828	)	$	(5,741,941	)

Issuance of Series A Convertible Preferred Stock for cash		13,333		13						-		-		99,987			-			100,000

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends		-		-		-		-		-		-		(211,305	)		-			(211,305	)

Issuance of common stock in connection with extension of notes payable		-		-						227,500		227		56,648			-			56,875

Reclassification of derivative liabilities to equity		-		-						-		-		345,830			-			345,830

Stock-based compensation:
Common stock		-		-		-		-		25,671		26		6,392			-			6,418

Net loss		-		-		-		-		-		-		-			(813,747	)		(813,747	)

Balance, March 31, 2020		1,258,416		1,258		-		-		27,329,933		27,330		15,673,117			(21,959,575	)		(6,257,870	)

Issuance of Series A Convertible Preferred Stock for cash		3,333		3						-		-		24,997			-			25,000

Issuance of common stock in connection with extension of notes payable		-		-						525,000		525		130,725			-			131,250

Issuance of warrants in connection with issuance of notes payable		-		-		-		-		-		-		161,256			-			161,256

Issuance of warrants in connection with issuance of advance payable		-		-						-		-		24,386			-			24,386

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends		-		-						-		-		(211,885	)		-			(211,885	)
Payment of dividends in kind		-		-						574,576		574		430,331			-			430,905

Stock-based compensation:
Common stock		-		-						1,270,000		1,270		316,230			-			317,500
Warrants		-		-						-		-		16,129			-			16,129

Net loss		-		-		-		-		-		-		-			(1,164,688	)		(1,164,688	)

Balance, June 30, 2020		1,261,749		1,261		-		-		29,699,509		29,699		16,565,286			(23,124,263	)		(6,528,017	)

Balance		1,261,749		1,261		-		-		29,699,509		29,699		16,565,286			(23,124,263	)		(6,528,017	)
Issuance of Series A Convertible Preferred Stock for cash		80,446		81						-		-		603,266			-			603,347

Issuance of common stock in exchange of accrued interest		-		-						265,534		266		66,383			-			66,649

Issuance of warrants in connection with issuance of notes payable		-		-						-		-		20,098			-			20,098

Series A Convertible Preferred Stock dividends:
Accrual of earned dividends		-		-						-		-		(226,191	)		-			(226,191	)

Stock-based compensation:
Options		-		-						-		-		103,600			-			103,600
Warrants		-		-						-		-		249,713			-			249,713

Net loss		-		-		-		-		-		-		-			(1,307,630	)		(1,307,630	)

Balance, September 30, 2020		1,342,195	$	1,342		-		-		29,965,043	$	29,965	$	17,382,155		$	(24,431,893	)	$	(7,018,431	)
Balance		1,342,195	$	1,342		-		-		29,965,043	$	29,965	$	17,382,155		$	(24,431,893	)	$	(7,018,431	)


[2]	Excludes shares of common stock underlying convertible notes that are expected to become convertible into shares of Series B Convertible Preferred Stock since such stock had not been designated by the Company as of ~~September~~June 30, 2022 and 2021.

	Accrued			Accrued
	Interest			Compensation			Total

Balance - January 1, 2021	$	539,836		$	84,953		$	624,789

Change in fair value		41,607			97			41,704
Issuance of warrants		(82,350	)		-			(82,350	)

Balance - March 31, 2021		499,093			85,050			584,143

Change in fair value		37,994			(9	)		37,985
Accrual of warrant obligation		164,857			-			164,857
Accrual of common stock obligation		-			7,097			7,097

Balance - June 30, 2021		701,944			92,138			794,082

Change in fair value		39,012			20			39,032
Issuance of common stock		-			(7,097	)		(7,097	)
Issuance of warrants		(165,216	)		-			(165,216	)

Balance - September 30, 2021	$	575,740		$	85,061		$	660,801

	●	Organ failure and transplantation. A variety of conditions can be treated by the transplantation of vital organs. However, transplantation is limited both by the insufficient supply of available donor organs and the need for lifelong, daily anti-rejection treatments post-transplant. Haploidentical organ transplants, with sustained chimerism, have the potential to make life saving transplants accessible to the majority of patients, with the prospect of improved life quality and expectancy.

	September 30, 2021			December 31, 2020			June 30, 2022			December 31, 2021

Cash	$	599,454		$	241,619		$	2,597		$	93,095
Restricted cash	$	-		$	3,500
Working capital deficiency	$	(10,187,899	)	$	(7,950,882	)	$	(10,766,559	)	$	(9,826,135	)

	●	Establishment of total enterprise or equity value;
	●	Analysis of equity rights for each class of security;
	●	Selection of appropriate model for valuation purposes;
	●	Determination of key valuation inputs; and
	●	Computation of the fair value of the subject security.

10.39(b)*	~~Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited.~~
31*	Certification of principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32*	Certification of principal executive officer and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	CELL SOURCE, INC.

Dated: ~~November 15, 2021~~December 2, 2022	By:	/s/ Itamar Shimrat
	Name:	Itamar Shimrat
	Title:	Chief Executive Officer and Chief Financial Officer (Principal Executive, Financial and Accounting Officer)